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SUMMARY
Attention-deficit/hyperactivity disorder (ADHD) is a neuropsychiatric disorder that 
starts in childhood and, in a large number of cases, persists into adulthood. 
Pharmacotherapy, often with stimulant medication, is considered to be one of the 
cornerstones in treatment of ADHD. Although the efficacy of short-term 
pharmacological treatment in adults with ADHD is well documented, research on 
long-term treatment outcome is scarce. Little is known about the course of the 
disorder in middle-aged and older adults.
The thesis presents two questionnaire surveys in adults with ADHD in different age 
groups, carried out in 2008-2010. The aim of the SIBBE2 study (n=1080, mean age 
36 years) was to investigate long-term outcome in a naturalistic sample of 
pharmacologically treated adults with ADHD. A survey of agreement between 
primary care physicians and patients on treatment of ADHD was part of the SIBBE 
study. The aim of the Fifty Plus study (n=251, mean age 56 years) was to investigate 
pharmacological treatment and quality of life in adults with ADHD who were fifty 
years and older. 
In the SIBBE study the response rate of 35 % was lower than expected. ADHD 
symptoms and impairment at baseline did not differ substantially between 
participants and non-participants. In the Fifty Plus study more than 59 % of the 
eligible sample could be included for further analyses. The mean observation time in 
the SIBBE study was 4.5 years, whereas it was 5.7 years in the Fifty Plus study.
We found that among participants, 4-5 years after initiation, the majority reported 
current psychopharmacological treatment for ADHD, most often with stimulant 
medication. The primary care physicians and their patients agreed on the 
pharmacological, but not the nonpharmacological treatments that had been given. 
Physicians and ADHD patients reported low levels of misuse of stimulant 
medication. Adults treated pharmacologically for more than 24 months reported 
significantly more favorable outcome than those treated for 24 months or less. Only a 
minority of participants reported levels of ADHD symptomatology and current 
2 SIBBE study on initiated treatment, treatment course and treatment evaluation (Studie om iverksatt 
behandling, behandlingsforløp og effektvurdering)
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functioning that could be classified as remission. Middle-aged and older adults with 
ADHD reported significantly reduced quality of life compared with population 
norms. Comorbidity at baseline, ADHD symptom severity, and unemployment were 
associated with poorer outcome.
The findings indicate that for many subjects the negative impact of ADHD persisted 
into late adulthood. Psychopharmacological treatment for more than two years was 
associated with better outcome and should probably be recommended for those who 
report improvement with this treatment without significant side effects. Primary care 
physicians can safely take responsibility for the psychopharmacological treatment of 
adults with ADHD when the condition is stable. For a majority of adults with ADHD 
comprehensive treatment approaches beyond ADHD symptom reduction are needed 
to improve outcome. Future studies on long-term multidimensional treatment 
programs for adults with ADHD are warranted.
13
ZUSAMMENFASSUNG
Die Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) beginnt im Kindesalter 
und kann häufig bis in das Erwachsenenalter fortsetzen. Die medikamentöse 
Behandlung, die hauptsächlich mit Stimulanzien durchgeführt wird, gehört zu den 
wichtigsten Bestandteilen der ADHS-Therapie. Die Nützlichkeit derselben als 
NXU]]HLWLJH WKHUDSHXWLVFKH 0DȕQDKPH LVW ZLVVHQVFKDIWOLFK JXW GRNXPHQWLHUW
Dahingegen mangelt es an Forschungsstudien, in denen der Behandlungsverlauf über 
einen längeren Zeitraum untersucht wurde. Bisher gibt es nur wenige Erkenntnisse 
darüber, wie sich das Symptombild von ADHS bei älteren Menschen äussert.
Diese Doktorarbeit befasst sich mit der Untersuchung von zwei unterschiedlich alten 
Gruppen von Erwachsenen mit ADHS. Die hauptsächlich durch Fragebögen 
erhobenen Daten wurden im Zeitraum von 2008 bis 2010 gesammelt. In der SIBBE3-
Studie (n=1060, Durchschnittsalter von 36 Jahren) war es das Ziel, eine natürliche 
Stichprobe von Erwachsenen mit ADHS zu untersuchen, die über einen längeren 
Zeitraum medikamentös für die ADHS behandelt worden waren. Eine 
Teiluntersuchung der SIBBE-Studie hat sich insbesondere mit dem Grad des 
Einvernehmens zwischen Arzt und Patient bezüglich der ADHS-Behandlung befasst. 
In der Fünfzig Plus-Studie (n=251, Durchschnittsalter von 56 Jahren) wurde sowohl 
die medikamentöse Behandlung als auch die Lebensqualität von älteren Erwachsenen 
mit ADHS untersucht.
Die Teilnahmequote in der SIBBE-Studie war mit 35 % geringer als erwartet. Unsere 
Analysen bezüglich der ADHS-Symptome sowie der Beeinträchtigung der 
generellen Funktionsfähigkeit haben aber keinen substantiell signifikanten 
Unterschied zwischen den Teilnehmern und denen, die nicht an der Untersuchung 
teilgenommen haben, aufgezeigt. In der Fünfzig Plus-Studie konnten 59 % der 
ursprünglichen Auswahl in die weitere Datenbearbeitung mit einbezogen werden. 
Die durchschnittliche Beobachtungszeit der SIBBE-Studie belief sich auf 4.5 Jahre, 
während dieselbe in der Fünfzig Plus-Studie bei 5.7 Jahren lag.
3 Studie von Behandlung, Behandlungsverlauf, und der Beurteilung therapeutischer Maßnahmen (Studie om 
iverksatt behandling, behandlingsforløp og effektvurdering)
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Die Mehrzahl der Teilnehmer gab zum Zeitpunkt beider Untersuchungen, das heisst 
4-5 Jahre nach Behandlungsbeginn an, gegenwärtig medikamentös für die ADHS 
behandelt zu werden. Die medikamentöse Therapie wurde hauptsächlich mit 
6WLPXODQ]LHQ GXUFKJHIKUW :LU EHREDFKWHWHQ HLQ JURȕHV (LQYHUQHKPHQ ]ZLVFKHQ
Hausarzt und Patient bezüglich der medikamentösen Therapie. Allerdings waren sich 
+DXVDU]WXQG3DWLHQWQLFKWVHKUHLQLJZDVDQGHUHWKHUDSHXWLVFKH0DȕQDKPHQEHWUDI
Der Missbrauch von Stimulanzien wurde von Hausärzten und Patienten 
übereinstimmend als gering eingeschätzt. Die Erwachsenen, die länger als zwei Jahre 
medikamentös für die ADHS behandelt worden waren, hatten ein signifikant 
besseres Resultat als diejenigen, die zwei Jahre oder kürzer in medikamentöser 
Behandlung gewesen waren. Dennoch war es letztendlich nur ein geringer Anteil der 
Teilnehmer, der eine mit der Normalauswahl vergleichbare ADHS-
Symptombelastung und allgemeine Funktionsfähigkeit erreichte. Im Vergleich zu 
einer gleichaltrigen Bevölkerung schätzten ältere Erwachsene mit ADHS ihre 
Lebensqualität als signifikant schlechter ein. Unsere Untersuchungen ergaben, dass 
GDV 9RUKDQGHQVHLQ YRQ SV\FKLDWULVFKHQ .RPRUELGLWlWHQ GDV $XVPDȕ GHU $'+6-
Symptombelastung und die Arbeitslosigkeit mit einem schlechteren Resultat 
assoziiert waren.
Unsere Befunde deuten darauf hin, dass die negativen Auswirkungen der ADHS für 
viele Patienten in das ältere Erwachsenenleben fortsetzen. Die medikamentöse 
Behandlung der ADHS für mehr als zwei Jahre war mit einem besseren Resultat 
verbunden und sollte wahrscheinlich für alle diejenigen als wünschenswert 
empfohlen werden, die eine derartige Therapie mit gutem Erfolg und ohne ernsthafte 
Nebenwirkungen vertragen können. Hausärzte können die Verantwortung für die 
medikamentöse Behandlung von Erwachsenen mit ADHS übernehmen. Dieses setzt 
jedoch voraus, dass der ADHS-Zustand zuvor therapeutisch hinreichend stabilisiert 
worden ist. Für die Mehrzahl der Erwachsenen mit ADHS besteht aber dennoch der 
%HGDUI YRQ XPIDVVHQGHQ WKHUDSHXWLVFKHQ 0DȕQDKPHQ GLH EHU GLH UHLQ
medikamentöse Behandlung hinausgehen. Dieses erfordert, dass der Einsatz von 
PHKUGLPHQVLRQDOHQ WKHUDSHXWLVFKHQ 0DȕQDKPHQ LQ GHU %HKDQGOXQJ YRQ
Erwachsenen mit ADHS und dessen Langzeiteffekt in zukünftigen Studien weiter 
untersucht werden.
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1. INTRODUCTION
1.1 Historical perspectives
Attention-deficit/hyperactivity disorder (ADHD) is the diagnostic term for a 
syndrome characterized by persistent problems of inattention, hyperactivity, and 
impulsivity (American Psychiatric Association 2000). Although scientific 
descriptions of the impairing problems with these symptoms can be traced back for 
more than two centuries (Barkley and Peters 2012;Crichton 2008;Still 1902), 
research on adults struggling with such problems first started in the late 1960s 
(Barkley et al. 2008).
By that time, the terminology of the syndrome already had changed many times 
primarily depending on the etiological concepts (Weiss and Hechtman 1993), e.g., 
hyperkinetic disease of infancy (Neumarker 2005), Minimal Brain Damage or 
Minimal Brain Dysfunction (Clements and Peters 1962), and hyperkinetic behavior 
syndrome in children (Laufer and Denhoff 1957). In 1968 the disorder was included 
in the diagnostic manuals as “hyperkinetic reaction of childhood” in the DSM4-II 
(American Psychiatric Association 1968), and a few years later as “hyperkinetic 
syndrome of childhood” in the ICD5-8 (World Health Organization 1974). 
Hyperactivity was seen as the primary marker, and exemplified by overactivity, 
restlessness, distractibility, and short attention span, especially in young children 
(American Psychiatric Association 1968). Generally, it was expected that “this 
syndrome tends to wane spontaneously and disappear” (Laufer and Denhoff 1957) 
by adolescence (American Psychiatric Association 1968).
Historically, it is often argued that the first scientific reference of the disorder can be 
found in Still’s Goulstonian lectures published in 1902 (Barkley 1998;Conners 
2000;Triolo 1999;Weiss and Hechtman 1993). Here Still described children who 
were characterized by a “lack of moral control”, an “incapacity for sustained 
attention”, overactivity, and “the immediate gratification of self without regard 
either to the good of others or to the larger and more remote good of self” (Still 
1902). Taylor (2011) has pointed out that although Still’s “descriptions of problem 
4 DSM Diagnostic and Statistical Manual of Mental Diseases
5 ICD International Classification of Diseases
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behavior certainly overlap with ADHD…” they “… do not give primacy to [the core 
symptoms of ADHD] impulsiveness, overactivity, or inattention (Taylor 2011).
The conceptualization and understanding of what today is known as ADHD changed 
when research showed that it was not over- or hyperactivity but “symptoms involving 
inability to sustain attention and to control impulsivity [that] can account for most of 
the deficits in the hyperactive group” (Douglas 1972).
Interestingly, investigations have found that descriptions of problems with attention 
had been published a long time before Still gave his lectures in the beginning of the 
19th century. For example, Crichton already in 1798 probably described what today is 
known as the “Inattentive Subtype of ADHD” (Palmer and Finger 2001). In his paper
on “attention and its diseases”, Crichton defined attention difficulties as “the 
incapacity of attending with a necessary degree of constancy to any one object”
(Crichton 1798, reprinted in the Journal of Attention Disorders 2008). Almost 
anticipating today’s knowledge about the impact of heredity on ADHD, he stated that 
this incapacity “either [can be] born with a person, or it may be the effect of 
accidental diseases. When born with a person it becomes evident at a very early 
period of life, and has a very bad effect, inasmuch as it renders him incapable of 
attending with constancy to any one object of education” (Crichton 2008).
Still, Crichton probably was not the first to address this issue in the medical 
textbooks. Barkley & Peters (2012) recently claimed that it was the German 
physician Weikard’s description of attention deficit (“Attentio Volubilis”) from 1775 
that might be the earliest scientific reference to ADHD (Barkley and Peters 2012). 
Indeed, Weikard’s presentation of attention deficits is quite in line with nowadays 
understanding of essential aspects of the disorder. In his book the following vivid 
description of attention problems is given: “An inattentive person won’t remark 
anything but will shallow everywhere. He studies his matters only superficially; his 
judgments are erroneous and he misconceives the worth of things because he does 
not spend enough time and patience to search a matter individually or by the piece 
with the adequate accuracy. Such people only hear half of everything; they memorize 
or inform only half of it or do it in a messy manner. According to a proverb they 
generally know a little bit of all and nothing of the whole” (Barkley and Peters 
2012).
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Interestingly, both Weikard and Crichton did not limit their descriptions to 
childhood, but included a possible persistence of these problems into adulthood. 
However, none of them actually described ADHD, because the diagnosistic 
definition of the disorder did not exist at that time (Singh 2008).
According to Barkley it was in the late 1960s that mainly three sources contributed to 
the growing understanding that ADHD not only was a childhood disorder, but also 
could persist into adulthood (Barkley et al. 2008). First, follow-up studies of 
hyperactive children showed that many had persistent problems into young 
adulthood (Menkes et al. 1967;Weiss et al. 1971). Second, family studies revealed 
that a number of parents of hyperactive children were considered to have been 
hyperactive themselves, and when assessed in adulthood were found to have 
increased rates of psychiatric problems (e.g. hysteria, sosiopathy, and alcoholism), 
whereas parents of adopted hyperactive children did not differ from normal controls 
(Cantwell 1972;Morrison and Stewart 1971;Morrison and Stewart 1973). The third 
source of evidence was upcoming descriptions of adults supposed to have been 
hyperactive during childhood, but who never had been diagnosed (Gomez et al. 
1981;Morrison 1979;Quitkin and Klein 1969;Shelley and Riester 1972).
Consequently, by the mid seventies for example Mann and Greenspan (1976) 
suggested that “adults who have had minimal brain dysfunction as children 
constitute a distinct diagnostic entity, adult brain dysfunction (ABD), which may 
exist alone or with a variety of other psychiatric syndromes” (Mann and Greenspan 
1976). Yet, the diagnostic manuals of DSM-III (American Psychiatric Association 
1980), DSM-III-R (American Psychiatric Association 1987), and DSM-IV 
(American Psychiatric Association 1994) did not include detailed criteria for ADHD 
in adults (Triolo 1999).
The American psychiatrist Wender (1995) was the first to describe a set of diagnostic 
criteria for ADHD in adults6 (Wender 1995). It has been argued that Wender’s 
diagnostic criteria, with an emphasis on mood lability, irritability, hot temper, and 
impaired stress tolerance as important associated features of the disorder (Wender 
1995), were not in line with the conceptualization of ADHD in the diagnostic 
6 UTAH Criteria for ADHD in Adults
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manuals (Barkley et al. 2008). Recent research on emotional lability and 
dysregulation in children, adolescents, and adults with ADHD (Barkley and Fischer 
2010;Retz et al. 2012;Sobanski et al. 2010;Surman et al. 2011) has shown that some 
of his diagnostic considerations are valuable for at least a subgroup of patients in the 
ADHD spectrum.
Nowadays scientific evidence support the understanding of ADHD as a 
neurobiological, highly heritable childhood disorder that in a number of cases can 
persist into adulthood (Biederman and Faraone 2005;Elia et al. 1999;Goldman et al. 
1998;Swanson et al. 1998). Obstetric complications and psychosocial adversities 
have been identified as some of the possible predisposing risk factors (Biederman 
and Faraone 2005). Still, no single test alone verifies the diagnosis of ADHD 
(Zametkin and Ernst 1999).
1.2 Diagnostic criteria, subtypes and prevalence of ADHD
1.2.1 Diagnostic criteria and subtypes of ADHD
According to ICD-10 DCR7 (World Health Organization 1993) and DSM-IV-TR8
(American Psychiatric Association 2000), hyperkinetic disorder and ADHD are 
defined by a total of 18 symptoms of inattention, hyperactivity, and impulsivity.
Symptoms must have persisted for at least six months to a degree that is maladaptive 
with the developmental level. Further, an onset before the age of seven years, and 
impairment in two or more settings and in social, academic or occupational 
functioning is required (American Psychiatric Association 2000;World Health 
Organization 1992). Symptoms of inattention, and hyperactivity, and impulsivity 
must not be better accounted for by another mental disorder (American Psychiatric 
Association 2000;World Health Organization 1993) (see Table 1 for a detailed 
overview of the diagnostic criteria for ADHD according to DSM-IV-TR).
7 DCR diagnostic criteria for research
8 TR text revision
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Table 1 Diagnostic criteria for Attention-Deficit/Hyperactivity Disorder according to DSM-IV-TR
A. Either (1) or (2): 
(1) six (or more) of the following symptoms of inattention have persisted for at least 6 months
to a degree that is maladaptive and inconsistent with developmental level: 
Inattention
(a) often fails to give close attention to details or makes careless mistakes in schoolwork, 
work, or other activities
(b) often has difficulty sustaining attention in tasks or play activities
(c) often does not seem to listen when spoken to directly
(d) often does not follow through on instructions and fails to finish schoolwork, chores, or 
duties in the workplace (not due to oppositional behavior or failure to understand 
instructions)
(e) often has difficulty organizing tasks and activities
(f) often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental 
effort (such as schoolwork or homework)
(g) often loses things necessary for tasks or activities (e.g., toys, school assignments, 
pencils, books, or tools)
(h) is often easily distracted by extraneous stimuli
(i) is often forgetful in daily activities
(2) six (or more) of the following symptoms of hyperactivity-impulsivity have persisted for at 
least 6 months to a degree that is maladaptive and inconsistent with developmental level:
Hyperactivity
(a) often fidgets with hands or feet or squirms in seat
(b) often leaves seat in classroom or in other situations in which remaining seats is 
expected
(c) often runs about or climbs excessively in situations in which it is inappropriate (in 
adolescents or adults, may be limited to subjective feelings of restlessness)
(d) often has difficulty playing or engaging in leisure activities quietly
(e) is often “on the go” or often acts as if “driven by a motor”
(f) often talks excessively
Impulsivity
(g) often blurts out answers before questions have been completed
(h) often has difficulty awaiting turn
(i) often interrupts or intrudes on others (e.g., butts into conversations or games)
B. Some hyperactive-impulsive or inattentive symptoms that caused impairment were present before
age 7 years.
C. Some impairment from the symptoms is present in two or more settings (e.g., at school [or work] 
and at home).
D. There must be clear evidence or clinically significant impairment in social, academic, or 
occupational functioning.
E. The symptoms do not occur exclusively during the course of a Pervasive Developmental 
Disorder, Schizophrenia, or other Psychotic Disorder and are not better accounted for by 
another mental disorder (e.g., Mood Disorder, Anxiety Disorder, Dissociative Disorder, or a 
Personality Disorder).
Adapted from the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text
revision, American Psychiatric Association, 2000.
Although the wording of the symptoms is nearly identical, the conceptualization of 
the disorder differs somewhat between the ICD and DSM systems. Whereas nearly 
identical nine symptoms for inattention are used in the manuals, the symptom “often 
talks excessively” in the ICD-10-DCR is allocated to impulsivity, while it is one of 
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the six symptoms of hyperactivity in the DSM-IV/DSM-IV-TR (American 
Psychiatric Association 1994;American Psychiatric Association 2000;World Health 
Organization 1993).
The ICD-10 diagnosis of hyperkinetic disorder requires the presence of all three core 
symptoms. On the other hand, one of three different subtypes of ADHD depending 
on the presence of symptoms of inattention, hyperactivity, and impulsivity can be 
diagnosed according to the DSM-IV (combined type, predominantly inattentive type, 
and predominantly hyperactive-impulsive type). For adolescents and adults who 
currently have symptoms but no longer meet the full criteria for the disorder, ADHD 
In Partial Remission can be coded for in the DSM-IV-TR (American Psychiatric 
Association 2000). The concept of ADHD identifies a broader group of subjects than 
hyperkinetic disorder, which is defined more rigorous with respect to pervasiveness 
and comorbidity (Lee et al. 2008;Remschmidt 2005;Tripp et al. 1999). A recent 
study showed that in a sample of children with a DSM-IV diagnosis of ADHD 
Combined type, only 25 % met criteria for hyperkinetic disorder (Santosh et al. 
2005). Although the question has been raised whether ADHD primarily is an 
American condition (Faraone et al. 2003), studies have shown that when trained 
clinicians used uniform, standardized criteria, the patient populations identified in 
samples in North America and outside of North America were generally very similar 
(Buitelaar et al. 2006). Nevertheless, it is challening that follow-up studies revealed 
only poor to modest subtype stability across age, and that so far no predictors of 
diagnostic stability across subtypes have been identified (Todd et al. 2008).
DSM-IV-TR and ICD-10-DCR do not specify separate diagnostic criteria for 
ADHD/hyperkinetic disorder in adults (Barkley et al. 2008;McGough and Barkley 
2004). The diagnostic criteria for ADHD have never been validated in adults, and 
until recently no developmental adjustment or specific diagnostic threshold of 
number of criteria for ADHD for adults was given (Barkley et al. 2008;McGough 
and Barkley 2004). DSM-IV-TR does not specify if the ADHD subtype assignment 
should be based on the symptom presentation in childhood or adulthood (Barkley et 
al. 2008;McGough and Barkley 2004). The manual highlights that the diagnosis of 
ADHD in adults should not solely be based on an adult’s recall of childhood 
problems with inattention, hyperactivity, and impulsivity, as this could be inaccurate 
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(American Psychiatric Association 2000). Whenever possible, collateral information 
should be asked for to complement retrospective data. In summary this means that 
adult ADHD still remains to be a primarily clinical diagnosis (McGough and Barkley 
2004).
1.2.2 Prevalence of ADHD
The prevalence of ADHD in school-age children has been estimated to be 3 % to 7 % 
(American Psychiatric Association 2000). In line with this, a recent meta-analysis 
found the worldwide prevalence of ADHD in school-age children to be 5.3 % 
(Polanczyk et al. 2007). Although a large variability of prevalence rates among 
studies was observed, this mainly could be explained by methodological differences 
across studies (Polanczyk et al. 2007). As hyperkinetic disorder is considered to be a 
less broader type of ADHD, comparable prevalence rates in school-age children 
consequently have been estimated to be somewhat lower, e.g., 1 % to 3 % 
(Remschmidt 2005). Interestingly, a recent population-based study among school-
age children in Europe found a prevalence rate of ADHD of 1.7 %. This result, 
which was much more in line with expected numbers for hyperkinetic disorder than 
the frequently reported prevalence rates for ADHD, was primarily explained by the 
inclusion of the impairment criteria, and methodological considerations regarding the 
data collection (Heiervang et al. 2007).
Follow-up studies of clinically referred samples of children with ADHD into 
adulthood revealed divergent rates of persistence, ranging from 4 % to 66 % 
(Barkley et al. 2002;Mannuzza et al. 1993;Mannuzza et al. 1998;Mannuzza et al. 
2002;Rasmussen and Gillberg 2000;Weiss et al. 1985). Ascertainment procedures, 
attrition rates, information sources, and different type of ADHD criteria applied in 
these studies have all been suggested as possible explanations for the reported 
variability of persistence (Barkley et al. 2002;Mannuzza et al. 2003). Based on some 
of the early findings from follow-up studies, Hill and Schoener (1996) estimated the 
prevalence of ADHD in adults at age 40 to be 0.05 % (Hill and Schoener 1996). 
Others have argued that differences in reported remission rates rather reflect the 
definition of the disorder, and not the course of it (Biederman et al. 2000). When 
residual symptoms and functional impairment were included in a meta-analysis of 
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follow-up studies, the rate of persistent ADHD in young adulthood was estimated to 
be around 65 % (Faraone et al. 2006).
It was not before the year of 2006 that the first population-based prevalence data of 
ADHD in adults aged 18-44 years were available. As part of the large NCS-R9 study, 
the prevalence of current adult ADHD in this age group in the USA10 was found to 
be 4.4 % (Kessler et al. 2006). The study also revealed that the majority of adults 
with ADHD were untreated, had several comorbid disorders, and had significantly 
elevated odds of disability in self-care, mobility and cognition (Kessler et al. 2006). 
Interestingly, adults older than 44 years of age were not included in this study 
because of concerns about recall failure (Kessler et al. 2006).
A cross-national study on prevalence rates of adult ADHD found an estimated 
average of 3.4 % (Fayyad et al. 2007). Although the aforementioned findings from 
Kesssler et al. in many ways were confirmed in this study, somewhat lower 
prevalence rates of ADHD in lower income countries (1.9%) were observed (Fayyad 
et al. 2007). Finally, a recent meta-analysis estimated the pooled prevalence of adult 
ADHD across included samples to be 2.5 % (Simon et al. 2009). Among the 
reviewed studies, only one (Kooij et al. 2005) had included older adults (e.g., up to 
75 years of age). Taken the limited findings with respect to study composition and 
mean age into consideration, the authors concluded that the prevalence of ADHD in 
adults seems to decline with age. At the same time they highlighted that as “some 
children do not outgrow the disorder but outgrow the diagnostic criteria”, the true 
prevalence of ADHD may be underestimated when diagnosing adult ADHD 
according to the current versions of the diagnostic manuals (Simon et al. 2009).
The male-female ratio in children ranges from 3:1 to 9:1 mainly depending on 
subtype and setting (American Psychiatric Association 2000;Elia et al. 1999). In 
younger adults with ADHD a more balanced gender distribution, and even a 
predominance of women in one study, has been reported (Biederman et al. 
1994;Biederman et al. 2004;Elia et al. 1999;Kessler et al. 2006).
9 NCS-R National Comorbidity Survey Replication
10 USA United States of America
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In the recently published fifth edition of the DSM (DSM-5) some changes with
respect to the diagnosis of ADHD have been made. The age of onset has been 
increased to prior to age 12 years. For older adolescents and adults a slightly lower 
diagnostic threshold with at least five out of six symptoms of inattention, and/or 
hyperactivity and impulsivity has been defined. The manual provides examples for 
all symptoms through parts of the lifespan, as well as it is required to specify the 
level of current severity from mild to severe (American Psychiatric Association 
2013). Still, no separate criteria for adults with ADHD are given.
This latest version of the DSM estimates a prevalence rate of 2.5% for ADHD in 
adults, whereas the male-female ratio is specified to be 1.6:1. These numbers are 
well in line with what has been referred to in this chapter of the thesis. Interestingly, 
until 2012 no epidemiological data on ADHD in older adults were available. A 
recently published study found a prevalence of ADHD of 2.8 % in adults aged 71-94
years, which fits quite well with the latest scientific guidance provided in the DSM-5
(American Psychiatric Association 2013;Michielsen et al. 2012).
1.3 Clinical characteristics of adult ADHD
In adults the symptom presentation of inattention, hyperactivity, and impulsivity 
typically is somewhat different from what is seen in children. For instance, most 
adults not longer “run or climb excessively in situations where this is inappropriate”
(American Psychiatric Association 2000), but they may well report about an inner 
restlessness, and an inability to slow down, to relax, or to work more than one job.
Hyperactivity can be expressed as excessive fidgeting (shaking knees, tapping hands 
or feet), difficulty sitting still for a long time when this is expected (in meetings, in 
the theatre or movie, and at home), a subjective feeling of always to be “on the go”, 
not to be able to just stay at home, or to talk excessively without being able to engage 
in a mutual conversation with a spouse, friends or significant others.
Impulsivity can be expressed as impatience (difficulty to wait for others to finish 
tasks or activities, waiting in line at a gasoline station, at bank machines, in 
supermarkets), acting without thinking (quitting a job without having any 
alternatives), dangerous driving, leaving and starting new relationships on impulse, 
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and blurting things out (difficult to wait for others to finish what they are talking 
about, saying what comes in their mind without considering the situational 
appropriateness), and sensation seeking behavior (impulsive sexual activities and 
dangerous life situations).
Whereas symptoms of hyperactivity and impulsivity often are found to decline with 
an increasing age (Biederman et al. 2000;Faraone et al. 2006;Mick et al. 2004), 
attention problems can become more prominent in adulthood (Kessler et al. 
2010;Kooij et al. 2010;Montano 2004). Thus, inattention can be expressed as 
difficulties in organizing and prioritizing tasks or activities (missed appointments, 
deadlines), completing tasks (postponing things endlessly, procrastination), 
difficulties with sustained attention in boring activities (reading a book without 
special interests, keep accounts, paying bills), distractibility, forgetfulness (don’t 
remember what to buy in the supermarket despite of a list, and even forget to pick up
own children from kindergarten), losing or misplacing things (keys, assignments, 
wallets), and feeling overwhelmed because of difficulties with mistakes in paperwork 
and time management. Inattention problems do not rule out that some exclusively 
can hyperfocus on one new, exciting or interesting activity.
Studies showed that the three core symptoms of the disorder only partly cover the 
challenges seen in daily life of many adults with ADHD (Haavik et al. 2010). 
Frequently reported symptoms of increased irritability, low frustration tolerance and 
emotional lability, as well as motivational problems may lead to even greater 
challenges in daily life (Asherson 2005;Gibbins and Weiss 2007;Haavik et al. 2010). 
Overall, the majority of adults with ADHD have been found to “live chaotic and 
disrupted lives” (Montano 2004).
1.4 ADHD in middle-aged and late adulthood
So far scientific research has been limited to younger adults with ADHD (Barkley 
2002), and little is known about the course of the disorder in middle-aged and late 
adulthood (Riccio et al. 2005).
The possibility of a persistence of ADHD also into middle-aged and late adulthood 
emerges from at least four different aspects. First, research has shown that the 
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disorder can persist into young adulthood, and persistence for the lifespan has been 
suggested (Faraone et al. 2006). Second, there is overwhelming evidence that ADHD 
is highly heritable (Faraone et al. 2005), and already early research showed that it in 
many ways “runs in families” (Morrison and Stewart 1971;Morrison and Stewart 
1973). Increasing availability of assessment and treatment for the disorder for adults 
contributes to the probability that both parents and grandparents will ask for an 
evaluation when they have recognized signs and symptoms of the disorder, after an 
often younger family member has been diagnosed with ADHD. Third, an increasing 
public awareness of ADHD in adults may cause that undiagnosed and untreated 
adults in all age groups will ask for an assessment for the disorder. The fourth aspect 
is highlighted through common clinical experience from assessment and treatment of 
middle-aged and older adults diagnosed with ADHD in late adulthood.
Until 2009 ADHD in middle-aged and older adults rarely had been discussed in the 
scientific literature (Matlen 2008a;Weiss et al. 2001). For example, as late as in 2008 
da Silva et al (2008), when reporting about a successful treatment of a 67-year-old 
woman with ADHD with MPH11, stated that they were unable to find reports of 
ADHD in elderly adults in the literature (da Silva and Louza 2008).
Probably one of the first broader descriptions of middle-aged adults with ADHD in 
the literature is given in a clinical crossroad article from 1998, published in JAMA12
(Biederman 1998;Parker and Hartman 1999). Weiss and colleagues (2001) briefly 
addressed the topic of becoming older with ADHD in their book “ADHD in 
Adulthood” in a chapter on future directions and challenges (Weiss et al. 2001). 
Wetzel et al (2008) described two cases of older adults with ADHD (Wetzel and 
Burke 2008); whereas Matlen (2008) presented the case of a grandmother who was 
diagnosed with ADHD when she was 75 years of age (Matlen 2008b).
In a series of 10 different studies on adults and elderly with neuropsychiatric 
disorders including ADHD that so far only has been published in Swedish, Lindqvist 
(2004) reported about 28 adults (15 men and 13 women) with a primary diagnosis of 
DAMP13/ADHD who had passed 50 years of age when interviewed (Lindqvist 
11 MPH methylfenidate
12 JAMA Journal of the American Medical Association
13 DAMP deficits in attention, motor control and perception (Gillberg 2003;Gillberg and Gillberg 1988) 
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2004). The majority of adults reported no reduction of their activity level compared 
to earlier years. Hyperactivity had changed to restlessness, which many had managed 
to live with. Almost 50 % of the sample reported a worsening of memory, especially 
short-term memory, compared with when they were younger. Problems with 
inattention were unchanged for a large majority. The persistence of economical 
problems due to unemployment, and social and interpersonal problems was striking. 
Many had medical and psychiatric problems, such as fibromyalgia and depression. 
Interestingly, almost 50 % stated that they were satisfied with their current life. For 
most of the reported outcomes no gender differences were found (Lindqvist 2004).
Whereas Kessler et al (2006) in their prevalence study on ADHD did not include 
adults older than 44 years of age because of concerns of recall failure (Kessler et al. 
2006), almost 50 % of the study sample in a European study on adult ADHD was 45 
years and older (Kooij et al. 2005). In the latter more women than men participated. 
A small decline of hyperactivity symptoms with increasing age was found, while no 
influences of age on symptoms of inattention and impulsivity were reported (Kooij et 
al. 2005).
In the lack of knowledge about the adult population with ADHD, and questions 
about the course of the disorder, treatment options and quality of life (QoL14) also in 
middle-aged and older adults should be studied.
1.5 Comorbidity in adults with ADHD
The term “co-morbidity” refers to “any distinct additional clinical entity that has 
existed or may occur during the clinical course of a patient having an index disease”
(Feinstein 1970). According to Feinstein, co-morbidity has at least “functional 
effects” on the patient with respect to anticipated outcome, and “diagnostic effects” 
on the clinician with the consequence that it may be difficult to identify the index 
disease (Feinstein 1970). In psychiatry, as pointed out by Maj (2005), the frequent 
use of the term comorbidity can become incorrect “because in most cases it is 
unclear whether the concomitant diagnoses actually reflect the presence of distinct 
14 QoL quality of life
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clinical entities or refer to multiple manifestations of a single clinical entity” (Maj 
2005).
In ADHD comorbidity is rather the rule than the exception, and it has been argued 
that “pure ADHD” actually may be an atypical variant of the disorder (Kadesjo and 
Gillberg 2001). The persistence of ADHD into adulthood has been found to be 
strongly associated with the presence of psychiatric comorbidity (Biederman et al. 
1995). Studies showed that psychiatric comorbidity had a large impact on treatment 
outcome in ADHD (The MTA Cooperative Group 1999b).
Millberger et al. (1995) investigated the influence of overlapping symptoms on the 
diagnosis of ADHD and frequently occurring comorbid disorders (i.e., major 
depression, bipolar disorder, generalized anxiety disorder) (Milberger et al. 1995). 
The investigators concluded that ADHD was not an artifact of symptoms that were 
shared with other psychiatric disorders (Milberger et al. 1995).
Recent investigations in school-aged children with primarily a diagnosis of ADHD 
combined type in both North-America and Europe found high rates of comorbid 
disorders, such as ODD15, anxiety, DCD16, and CD17 (Kadesjo and Gillberg 
2001;The MTA Cooperative Group 1999a). The majority of these children had at 
least two comorbid disorders, and the “pure type of ADHD” was rare. Studies in 
adults with ADHD revealed a similar picture with increased rates of comorbid 
disorders compared to controls (i.e., anxiety disorder, mood disorder, personality 
disorder, and SUD18), and more than 60 % having at least one comorbid disorder 
(Biederman et al. 1993;Kooij et al. 2004;Sobanski 2006). Similar results have been 
reported in a recent epidemiological study where adult ADHD was found to be 
significantly comorbid with many other 12-month DSM-IV disorders (Kessler et al. 
2006). Studies also showed that there was limited evidence for gender differences 
with respect to psychiatric comorbidity (Biederman et al. 1994;Biederman et al. 
2004;Mannuzza and Gittelman 1984). High rates of lifetime comorbidity (87 %) 
15 ODD oppositional defiant disorder
16 DCD developmental coordiantion disorder
17 CD conduct disorder
18 SUD substance use disorder(s)
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were found in a sample of European adults with ADHD followed at an outpatient 
psychiatric clinic (Torgersen et al. 2006).
Although there is an overall acknowledgement of increased rates of comorbid 
conditions in adults with ADHD, reported prevalence rates and type of psychiatric 
comorbidity varies considerably depending on factors such as study design (e.g., 
prospective or retrospective), and sample collection (Marks et al. 2001;Sprafkin et al. 
2007). Whereas most prospective and retrospective studies reported increased rates 
of anxiety disorders, mood disorders, personality disorders, and SUD (Biederman et 
al. 1994;Biederman et al. 2006c;Biederman et al. 2006d;Fischer et al. 2002;Murphy 
and Barkley 1996;Murphy et al. 2002;Philipsen 2006;Rasmussen and Gillberg 
2000;Shekim et al. 1990;Sobanski et al. 2007), others found no statistical difference 
of affective or anxiety disorders when adults with ADHD were compared to controls 
(Mannuzza et al. 1993;Mannuzza et al. 1998). In addition, increased rates of 
neurodevelopmental disorders, learning difficulties, and sleep disorders have been 
reported (Philipsen et al. 2006;Rasmussen et al. 2001;Rasmussen and Gillberg 
2000;Schredl et al. 2007). Whereas some studies reported differences between 
clinical and nonclinical samples, and for the different subtypes of ADHD (Sprafkin 
et al. 2007), others could not confirm such findings (Able et al. 2007;Biederman et 
al. 2005a;Sobanski et al. 2008). Although increased lifetime prevalence of 
psychiatric comorbid disorders was found to be significantly different in samples of 
adults with ADHD compared to controls (Biederman et al. 2006c;Biederman et al. 
2006d), the one-year prevalence rates for mood and anxiety disorders were low, and 
not significantly different from controls in at least one of these studies (Biederman et 
al. 2006d).
In summary, increased rates of especially psychiatric comorbid disorders consistently 
have been reported in clinical and nonreferred samples of adults with ADHD. Most 
studies have investigated samples of younger adults with ADHD and little is known 
about the course of the disorder and the impact that comorbidity might have in 
middle-aged and older adults. Interestingly, in cases where adults with ADHD had 
found strategies to cope with their deficits, outcome was not always poor (Shekim et 
al. 1990).
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Whether medical conditions influence outcome has rarely been investigated. ADHD 
has been found to be associated with an increased risk for major injuries and asthma 
that may affect life expectancy. Moreover, an increased risk for cardiovascular 
disease, which might have implications for psychopharmacological treatment, has 
been suggested (Barkley 2002).
1.6 Treatment
1.6.1 Psychopharmacological treatment of adults with ADHD
Pharmacotherapy, most often with stimulant medication, is one of the cornerstones in 
treatment of the core ADHD symptoms across the lifespan (Elia et al. 1999;Swanson 
et al. 1998).
Historically, Bradley (1937) was the first to describe the effects of Benzedrine 
(racemic amphetamine) on learning and emotional state in children with a variety of 
behavioral disorders (Bradley 1937). It was not before the 1960s that improvement in 
attention span, reduced hyperactivity and impulsivity, a better motor coordination, 
and an increase of useful productivity in children with MBD19/ADHD became the 
main targets of psychopharmacological treatment, primarily with Ritalin®
(methylphenidate) (Clements and Peters 1962;Douglas 1972;Knobel 1962;Lange et 
al. 2010;Taylor 2011).
Probably one of the first descriptions in the literature of treatment with stimulant 
medication of adult ADHD is by Arnold et al. (1972). In a double blind, single case 
study they compared treatment with amphetamine and placebo in a young male adult 
patient with a previously undiagnosed hyperkinetic syndrome. Treatment with 
stimulant medication resulted in increased concentration, but also decreased anxiety 
and increased depression (Arnold et al. 1972). Arnold suggested a “paradoxical 
calming” effect of stimulant medication, but this hypothesis was disproved in a study 
by Rapoport et al. (1980) where no unique stimulant response in hyperactive children 
was found compared to normal controls (Rapoport et al. 1980).
19 MBD minimal brain disorder or dysfunction
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Over the next three decades a number of open or double-blind placebo controlled 
studies of treatment with MPH (Bouffard et al. 2003;Gualtieri et al. 1985;Kooij et al. 
2004;Mattes et al. 1984;Spencer et al. 1995;Spencer et al. 2005;Wender et al. 
1985;Wood et al. 1976) and amphetamine (Paterson et al. 1999;Spencer et al. 2001) 
were performed in adults with ADHD.
A meta-analysis of the efficacy of MPH in treatment of adults with ADHD from 
2004 found a large effect size (between 0.9 and 1.3 depending on optimized high 
doses of MPH and physician ratings of outcome rather than patients’ self-report) 
(Faraone et al. 2004). This investigation included only six studies with a total of 140 
MPH-treated adults with ADHD (Faraone et al. 2004). As pointed out by others, 
most studies also had a short observation time (4-12 weeks) (Myhre 2005). Despite 
that many of the participants reported improvement on treatment with stimulant 
medication, quite a lot did not, and side effects were mentioned frequently in both 
treatment and placebo groups (Myhre 2005).
The efficacy of newly developed long-acting compounds in adults with ADHD has 
been shown in several randomized placebo-controlled studies, such as for Concerta£
(OROS methylphenidate) (Biederman et al. 2006b), Strattera£ (atomoxetine) 
(Michelson et al. 2003;Spencer et al. 1998), and mixed amphetamine-salts 
(Adderal£) (Spencer et al. 2001;Weisler et al. 2006). Yet, a comparative review on 
benefits and harms of competing medications for adults with ADHD found that 
immediate-release MPH still should be considered to be the first-line treatment for 
the majority of adults with the disorder (Peterson et al. 2008).
Extended use of psychopharmacological treatment in adults with ADHD more 
recently was challenged due to a suspected risk of serious cardiovascular side effects 
(Biederman et al. 2006e;Nissen 2006), a lack of long-term follow-up data (Myhre 
2005;Spencer et al. 2004;Torgersen et al. 2008), high attrition rates in open label 
treatment studies (Biederman et al. 2005b;Wilens et al. 2005), and poor adherence to 
treatment with stimulant medication (Perwien et al. 2004;Swanson 2003;Torgersen et 
al. 2008). Several researchers pointed out that study samples included in clinical 
trials only to a limited degree reflect the variation in adult ADHD seen in clinical 
practice (Surman et al. 2010;Weiss et al. 2006). With respect to 
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psychopharmacological treatment of middle-aged and older adults with ADHD until 
2008 only limited scientific information was available (Weiss et al. 2001).
Summarizing current knowledge on psychopharmacological treatment of adult 
ADHD, Torgersen et al. (2008) concluded, “both clinicians and patients should not 
be dazzled by the initial good response that may come” (Torgersen et al. 2008). For 
many adults pharmacotherapy for ADHD will not be sufficient for remission of the 
disorder.
1.6.2 Psychosocial treatment of adults with ADHD
The need for nonpharmacological and psychosocial interventions in treatment of 
adults with ADHD emerges from different aspects. There are several limitations in 
the effect of psychopharmacological treatment as mentioned above (Dulcan 
1997;Taylor et al. 2004). A substantial number of adults with ADHD are considered 
to be nonresponders to pharmacotherapy because of insufficient symptom reduction, 
or that they cannot tolerate this kind of treatment (Safren et al. 2004). Even among 
those who are considered responders to pharmacotherapy, symptom reduction often 
seems not to be optimized because of a lack of strategies to handle associated 
functional impairment (Safren et al. 2004). Finally, some adults with ADHD may be 
skeptical to pharmacotherapy, and prefer nonpharmacological interventions. Thus, 
multimodal interventions, e.g., involving psychoeducation and psychotherapy, have 
been strongly recommended as the first choice of appropriate treatment for adults 
with ADHD (Gibbins and Weiss 2007;Nutt et al. 2007;Wender et al. 2001). Being 
diagnosed with ADHD in adulthood, for many will start a process where one has to 
reconciliate with the past, manage the emotional impact of the diagnosis, and to 
make considerations for the future (Bemporad 2001;Young et al. 2008).
Wiggins et al. (1999) were among the first to show that a structured brief group 
intervention could result in significant improvement in adults with ADHD (Wiggins 
et al. 1999). Likewise did a cognitive remediation group program (Stevenson et al. 
2002), and a structured skill training group program based on the principles of 
cognitive-behavioral treatment for borderline personality disorder (Hesslinger et al. 
2002;Philipsen et al. 2007) revealed significant improvements in ADHD 
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symptomatology and associated features. Others investigated the advantage of 
individual based CBT20 approaches for ADHD treatment (Safren 2006). A 
combination of pharmacotherapy with CBT or problem-focused therapy was found 
to be associated with significant improvements in clinical outcomes (Rostain and 
Ramsay 2006;Weiss and Hechtman 2006). Self-directed psychosocial intervention 
with only limited therapist contact, was found only to be successful when adults with 
ADHD were able to closely adhere to the program (Stevenson et al. 2003).
Despite these promising findings, upon 2007 the empirical evidence for the efficacy 
of psychosocial approaches and psychotherapy in treatment of adults with ADHD 
still was considered to be limited (Murphy 2005;Murphy 1998;Ramsay 2007).
1.7 Outcome
1.7.1 Prospective follow-up studies from childhood to adulthood
ADHD in children, adolescents and young adults is considered to be a treatable 
condition, but the impact of treatment on outcome has been questioned (Biederman 
and Faraone 2005;Elia et al. 1999;Faraone 2005;Goldman et al. 1998;Swanson et al. 
1998).
The value of well-designed longitudinal studies is to “answer questions which cross-
sectional data cannot answer” (Sexton 1963). In the field of ADHD four longitudinal 
studies have been published that have followed children with the disorder into young 
adulthood [e.g., the Montreal study (Weiss et al. 1985), the New York study 
(Mannuzza et al. 1993), the Gothenburg study (Rasmussen and Gillberg 2000), and 
the Milwaukee study (Barkley et al. 2002)]. As mentioned in Chapter 1.2.2, these 
studies differ on several important aspects, e. g., disorder criteria (for example 
different inclusion criteria for the Gothenburg and the New York study), attrition 
rates (up to 35 % in the Montreal study), reporting sources (for example self-report 
versus parent report), and ascertainment procedures (clinically referred in the 
Montreal, New York and Milwaukee studies versus community based in the 
Gothenburg study) (Mannuzza et al. 2003). Therefore, any interpretation of outcome 
20 CBT cognitive behavior therapy 
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data of a persistence of ADHD into adulthood from these studies has to take the 
aforementioned limitations into consideration.
Overall and on a group level, outcome of young adults with ADHD in all studies was 
“worse than expected” (Rasmussen and Gillberg 2000). Compared to controls, young 
adults with ADHD had significantly higher rates of antisocial personality disorder 
(Fischer et al. 2002;Mannuzza et al. 1998;Rasmussen and Gillberg 2000;Weiss et al. 
1985), SUD (Barkley et al. 2004;Fischer et al. 2002;Mannuzza et al. 
1998;Rasmussen and Gillberg 2000), other personality disorders (Fischer et al. 
2002), and criminality (Fischer et al. 2002;Rasmussen and Gillberg 2000). The 
increased risk for criminality in adulthood was mediated by the development of CD 
and SUD in adolescence (Fischer et al. 2002;Mannuzza et al. 1998).
Whereas results from the New York study indicated that ADHD even in the absence 
of comorbid CD in earlier years increases the risk for antisocial personality disorder 
and SUD in adolescence (Mannuzza et al. 1998), a 30 year follow-up study of 
hyperactive boys with and without CD did not find an increased risk for later 
criminality in those without CD (Satterfield et al. 2007). A European follow-up study 
found girls with ADHD and conduct problems to have elevated risk of a psychiatric 
admission in adulthood (Dalsgaard et al. 2002) With respect to mood disorders some 
reported increased rates (Fischer et al. 2002), whereas others did not find 
significantly higher rates of mood or anxiety disorders (Mannuzza et al. 1998).
Compared to controls outcome of childhood ADHD in young adulthood showed 
more problems on major life activities such as educational, occupational, financial, 
social, and sexual functioning (Barkley et al. 2006;Mannuzza et al. 1997). 
Longitudinal studies also showed that a majority of young adults with ADHD were 
employed (Borland and Heckman 1976;Mannuzza et al. 1997), and that ADHD for 
some did not “preclude attaining high educational and vocational goals” (Mannuzza 
and Klein 2000).
Although individual characteristics (i.e., intelligence, emotional instability, low 
frustration tolerance), and family parameters (i.e., socioeconomic class, mental 
health of family members) have been found to be important predictor variables, it has 
been argued that it is the “multitude of interacting factors” that predict outcome 
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(Hechtman et al. 1984b;Hechtman 1991;Hechtman 1999;Mannuzza et al. 1998). The 
prediction of outcome in general probably still may be summarized best as done by 
Cantwell and Hechtman several years ago. They categorized outcome in adulthood 
generally to fall into three groups: a fairly normal outcome (developmental delay); a 
persistence of attentional, social, emotional, and impulse problems (continual 
display); and an outcome with serious psychiatric and/or social pathology 
(developmental decay) (Cantwell 1985;Cantwell 1996;Hechtman et al. 
1984b;Hechtman 1991).
The impact of long-term stimulant treatment on outcome, either alone or in 
combination with psychosocial interventions, has been beyond the expectations and 
“mostly disappointing” (Hechtman et al. 1984a;Jensen et al. 2007;Molina et al. 
2007;Satterfield et al. 2007). On the other hand, two of the longitudinal studies 
provided some scientific evidence that early treatment with stimulant medication did 
not increase the risk for development of SUD in adolescence and young adulthood 
(Barkley et al. 2003;Mannuzza et al. 2008).
1.7.2 Functional impairment
The diagnosis of ADHD or hyperkinetic disorder requires not only a persistent 
pattern of inattention, hyperactivity, and impulsivity with an onset before the age of 
seven, but also the presence of impairment in two or more domains (American 
Psychiatric Association 2000;World Health Organization 1993).
It is “impairment and not [the] diagnosis that is the indication for treatment” (Weiss 
et al. 2001). Indeed, the relationship between symptoms of ADHD and impairments 
mostly has been found to be not stronger than modest to weak (Barkley et al. 
2008;Gordon et al. 2006;Weiss et al. 2001). In clinical practice this means “someone 
can display the full range of ADHD-type symptoms without necessarily displaying 
significant impairment. Conversely, one can also show few ADHD symptoms and 
still suffer significant maladjustment…”(Gordon et al. 2006). For adults with ADHD 
the issue of a “symptomatic persistence”, i.e., a partial diagnostic status of ADHD 
with impairment has been pointed out to be important (Faraone et al. 2006;Mick et 
al. 2004).
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In both diagnosed and undiagnosed samples of adults with ADHD several domains 
consistently have been found to be impaired when compared to controls. Thus, the 
impairment leads to psychosocial disabilities such as lower educational attainment 
(Able et al. 2007;Barkley et al. 2006;Biederman et al. 1993;Biederman et al. 
2006a;Heiligenstein et al. 1999;Mannuzza et al. 1993;Mannuzza et al. 1997;Murphy 
and Barkley 1996), lower levels of employment (Able et al. 2007;Biederman et al. 
2006a), lower work performances (De Graaf et al. 2008;Kessler et al. 2005a;Murphy 
and Barkley 1996), lower occupational achievement (Borland and Heckman 
1976;Mannuzza et al. 1997;Matza et al. 2005a), and lower socioeconomic status 
(Able et al. 2007;Biederman et al. 1993;Borland and Heckman 1976).
Studies also have shown an association between ADHD and increased healthcare 
costs (Birnbaum et al. 2005;Harpin 2005;Hinnenthal et al. 2005;Matza et al. 
2005a;Secnik et al. 2005). Adults with ADHD reported more often about problems 
of family dysfunction, poorer marital adjustment, and higher rates of separation and 
divorce (Biederman et al. 1993;Biederman et al. 2006a;Eakin et al. 2004;Harpin 
2005;Murphy and Barkley 1996). Increased driving risks and higher numbers of 
traffic citations compared to controls have also been observed in adults with ADHD 
(Able et al. 2007;Barkley and Cox 2007).
According to Barkley (2008) the total impairment across domains, and the number of 
domains often impaired (pervasiveness), together account for the severity of ADHD 
in adults (Barkley et al. 2008). Others have argued that not necessary the severity of 
ADHD, but the “impairment relative to one’s potential” should be a sufficient 
justification for treatment (Weiss et al. 2001).
1.7.3 Quality of Life (QoL) in adults with ADHD
Patients’ QoL has become an important aspect of outcome in medicine (Felce and 
Perry 1995;WHOQoL 1995). In line with recommenations from the WHO21, QoL 
can be defined as “individuals’ perception of their position in life in the context of the 
culture and value systems in which they live and in relation to their goals, 
expectations, standards and concerns” (WHOQoL 1995). The definition underline 
21 WHO World Health Organization
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that one’s perception of QoL is subjective, influenced by both positive and negative 
aspects of life, and is multi-dimensional (Felce and Perry 1995;WHOQoL 1995). For 
subjective wellbeing positive affect, negative affect, and life satisfaction all have 
been identified as separate, and important components (Diener 1984;Diener et al. 
1985).
While QoL is broadly conceptualized, health-related quality of life (HRQoL22) more 
specific refers to “those aspects of an individuals’ life that impact directly upon their 
health” (Guyatt et al. 1993). Studies showed that medical and mental illness have an 
important impact on an individual’s QoL (Dodel et al. 2007;Ervik et al. 2006;Melle 
et al. 2005;Michalak et al. 2005;Spitzer et al. 1995;Stewart et al. 1989). 
Investigations also revealed that patients with the same clinical criteria assessed for 
HRQoL could react and feel quite differently (Guyatt et al. 1993).
In adults with ADHD research about associations between the disorder and HRQoL 
has been limited (Rimmerman et al. 2005). Clinical trials on psychopharmacological 
treatment of ADHD in adults primarily have investigated efficacy and safety, and did 
not include HRQoL as a natural outcome measure (Adler et al. 2006b). The limited 
number of studies that have investigated HRQoL found younger adults with ADHD 
to report reduced HRQoL when compared to controls (Adler et al. 2006b;Grenwald-
Mayes 2002;Rimmerman et al. 2005). Similiar results have been reported from 
studies that had investigated HRQoL in children and adolescents with ADHD 
(Klassen et al. 2004;Matza et al. 2004).
Assessment of QoL and HRQoL can be carried out with a generic instrument that 
provides a summary of several areas, or a disease specific instrument that extract 
more specific problems associated with the disorder. In the absence of a disease-
specific quality of life instrument for adults with ADHD, Brod and colleagues 
developed and validated the Adult attention-deficit/hyperactivity quality of life scale 
(AAQoL23), an instrument that was based on an increased awareness of the impact of 
ADHD symptoms and associated functional impairment on quality of life in adults 
with the disorder (Brod et al. 2005;Brod et al. 2006;Matza et al. 2007).
22 HRQoL health-related quality of life
23 AAQoL adult attention-deficit/hyperactivity quality of life scale
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Although short-term intervention studies, lasting not longer than eight weeks, 
provided some initial evidence that pharmacotherapy significantly improved 
measures of mental health and ameliorated ADHD symptoms, the impact of long-
term treatment on QoL in adults with ADHD so far has not been investigated 
satisfactory (Adler et al. 2006b). Information on functional impairment and quality of 
life in middle-aged and older adults with ADHD is scarce.
1.8 Unsolved research issues
Based on what has been presented in the previous chapters of the thesis, several 
unsolved research issues of treatment and outcome in adults with ADHD in different 
age groups arises.
Although the efficacy of short-term ADHD pharmacotherapy on the core symptoms 
of the disorder in adults is well documented, long-term follow-up studies are 
warranted to investigate the impact of such treatment on outcome (Myhre 
2005;Spencer et al. 2004;Torgersen et al. 2008). This is even more necessary as 
studies of long-term treatment of children and adolescents with ADHD (e.g., MTA24
study) have reported mixed results (Jensen et al. 2007;Swanson et al. 2007; Weiss et 
al.1975). Already in the early stages of treatment of ADHD, Weiss et al. (1975) 
summarized their findings after 3 to 5 years of treatment with stimulant medication 
in the following way: “Our impression was that methylphenidate was helpful in 
making hyperactive children more manageable at home and at school, but did not 
significantly affect their outcome after 5 years of treatment” (Weiss et al. 1975). 
With respect to adults with ADHD the long-term impact of pharmacotherapy on 
outcome still is unresolved.
The identification of variables associated with better outcomes in adults with ADHD 
is important for the development of appropriate treatment plans and public health 
strategies. So far factors such a family history of ADHD, psychiatric comorbidity 
and psychosocial adversity have been identified as possible predictors of a 
persistence of ADHD into adulthood (Biederman 2005), but studies showed that 
outcome primarily seemed to be defined through a cumulative interaction of 
24 MTA Multimodal Treatment Study of Children with ADHD
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individual characteristics, family parameters, and treatment (Hechtman 1999). One 
obvious limitation of these findings is that most studies have been performed in 
North America with a somewhat different set of social and cultural condtions 
compared to Non American societies.
Samples of adults with ADHD participating in randomized controlled treatment trials 
do to a large degree not reflect the variety of patients seen in the clinic (Surman et al. 
2010;Weiss et al. 2006). Therefore, more information on treatment outcome in 
naturalistic samples of adults with ADHD is needed.
Use and persistence of psychopharmacological treatment in adults with ADHD is 
still an unsolved research issue. From clinical trials high attrition rates have been 
reported (Myhre 2005;Spencer et al. 2004;Torgersen et al. 2008). Chart reviews on a 
continuity of MPH treatment in adults with ADHD revealed only short periods of 
adherence to treatment (Olfson et al. 2007;Perwien et al. 2004). Many of these 
studies have been performed outside of Europe and do by this reflect the somewhat 
different structure of society and public welfare system that may have hampered 
persistence and adherence to treatment than found in Europe.
The issue of a persistence of ADHD into middle-aged and late adulthood has hardly 
been discussed in the scientific literature (da Silva and Louza 2008;Weiss et al. 
2001;Wetzel and Burke 2008). Limited information has been available on course, 
treatment, and outcome (e.g., impairment and QoL) in these age groups (Barkley 
2002;Weiss et al. 2001). With an increased awareness of a lifelong persistence of 
ADHD, research about how the disorder looks like and what happens in middle-aged 
and late adulthood is of emerging interest. For example, are the core features of 
ADHD similar to what has been reported in younger age groups; can ADHD 
predispose the development of cognitive decline in late adulthood; does ADHD 
influence physical health and morbidity in late life; how have older adults managed 
to live with their ADHD symptoms; and can they tolerate and have benefit from 
treatment with stimulant medication?
According to The Norwegian Prescription Database the number of adults aged 50 to 
79 years who had purchased at least one prescription of stimulant ADHD medication 
during a year, had increased substantially from 2004 to 2008. Whereas a total of 280 
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subjects in these age groups were registred in 2004, the total number had rised to 738 
subjects by 2008, and the largest growth was observed for those between 50 to 59 
years of age (Norwegian Prescription Database 2013). Prescription of stimulant 
medication in Norway is restricted to treatment of ADHD and narcolepsy. 
Narcolepsy is a rare, underdiagnosed and often untreated condition (Heier et al. 
2009;Norwegian Board of Health Supervision 1998). The increase of prescription 
rates of stimulant medication in these age groups from 2004 to 2008 therefore most 
probably was a consequence of an increased awareness on and treatment of ADHD 
in Norway.
As the public awareness of a persistence of ADHD into adulthood at least in some 
parts of the world is growing, there is an increasing pressure for evaluation and 
treatment, with an equivalent demand for PCPs25 to take responsibility for treatment 
of ADHD (Hinshaw et al. 2011;Pottegard et al. 2012;Schlander et al. 2007;Turgay et 
al.2012). According to international guidelines, pharmacotherapy for adults with 
ADHD should be started by a specialist and can be transferred to PCPs for further 
consultations and control when the patients’ condition is stable (National Institute for 
Health and Clinical Excellence 2008; The Norwegian Directorate of Health 2007).
Concerns have been raised about whether or not PCPs are prepared to take on this 
responsibility (Thapar and Thapar 2002), and research on management of adult 
ADHD by PCPs has been sparse (Olfson et al. 2013).
Finally, the physician-patient relationship has been found to be important for 
patients’ satisfaction, treatment adherence, and outcome (Adams and Drake 2006). In 
the field of adult ADHD this issue has not been investigated extensively. For 
instance, the physician-patient relationship might be particularly vulnerable due to 
some of the clinical characteristics of the adult patient with ADHD (e.g., being late to 
or missed appointments, irritability, poor compliance), as well as some concerns 
about insufficient knowledge and treatment experience about adult ADHD among 
PCPs (Adler et al. 2009).
25 PCP primary care physican
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2. AIMS
The overall aims of the thesis were 
 to study use and persistence of psychopharmacological treatment for ADHD 
in different age groups of adults with the disorder (addressed in Papers I and 
III), 
 to study the physician-patient agreement on treatment for ADHD (addressed 
in Paper II), 
 to investigate the current functioning and quality of life of adults with AHDH 
in different age groups (addressed in Papers II and IV), and 
 to study to which extent psychopharmacological treatment for ADHD might 
impact outcome (addressed in Papers I, II, and III).
The thesis is based on two samples of adults with ADHD in different age groups. 
The younger sample of adults in the SIBBE study had a mean age of 36.5 years at 
follow-up. The older sample of adults in the Fifty Plus study had a mean age of 55.8 
years when assessed. Results from the SIBBE study are presented in Papers I and II, 
whereas results from the Fifty Plus study can be found in Papers III and IV.
In Paper I we investigated the long-term outcome of psychopharmacologically 
treated adults with ADHD in a naturalistic setting. The aims of this study were:
 to investigate current use of ADHD pharmacotherapy,
 to measure ADHD symptomatology and mental health functioning at follow-
up,
 to investigate the relationship between time on psychopharmacological 
treatment and outcome, and
 to identify possible predictors of outcome.
In Paper II we primarily studied aspects of psychopharmacological treatment for 
ADHD as reported by patients and their primary care physicians. The aims of this 
study were:
 to investigate primary care physician-patient agreement on use and misuse of 
stimulant medication,
 to investigate primary care physician-patient agreement on 
nonpharmacological treatment for ADHD, and
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 to investigate the agreement between patients’ self-report and primary care 
physicians’ clinical judgment of the patients’ functioning.
In Paper III psychopharmacological treatment of middle-aged and older adults with 
ADHD was investigated in a relatively large sample of adults 50 years of age and 
older. The aims of this study were
 to investigate use and persistence of psychopharmacological treatment for 
ADHD in this age group, and
 to explore the association between current psychopharmacological treatment 
for ADHD and ADHD symptoms, life satisfaction and psychosocial factors.
In Paper IV we investigated the impact of ADHD on quality of life in a sample of 
adults aged fifty years of age and older. The aims of this study were
 to investigate health-related quality of life and satisfaction with life compared 
with populations norms, and
 to identify patient characteristics associated with better quality of life.
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3. MATERIAL AND METHODS
3.1 The expert teams for hyperkinetic disorder/ADHD
Treatment of adults with ADHD with stimulant medication in Norway officially was 
not permitted until 1997 (Norwegian Board of Health Supervision 1997). 
Nevertheless, this did not preclude that as late as in 1996 some Norwegian clinicians 
could report on a case study of treatment with amphetamine of five adults diagnosed 
with ADHD and imprisoned for serious crime of violence (Stovner et al. 1996).
In 1997 the Norwegian Parliament unanimously voted that National Health 
Authorities should consider to establish a competence center at one of the regional 
hospitals, and to give access to treatment of “MBD26-patients” 18 years of age and 
older (Standing Committee on Health and Social Affairs 1997). In line with the 
resolution, National Health Authorities then appointed three regional 
multidisciplinary part-time working expert teams for hyperkinetic disorder/ADHD to 
secure assessment, diagnosis and treatment of adults with ADHD with stimulant 
medications for a period that in the end lasted until spring 2005. Also, the expert 
teams should assist National Health Services to increase the knowledge and 
competence on ADHD in adults (Norwegian Board of Health Supervision 1998), and 
to conduct a follow-up study among those adults with ADHD who had been treated 
with stimulant medication for a period of at least 24 months (Norwegian Board of 
Health Supervision 1999). In the regulations given, the National Health Authorities 
underlined that treatment with stimulant medication (available at that time were 
immediate release Ritalin®, and an immediate release amphetamine compound called 
Dexamin®), should be part of an individualized, comprehensive treatment plan 
(Norwegian Board of Health Supervision 1997;Norwegian Board of Health 
Supervision 1998). Treatment of adults with ADHD with stimulant medication as 
scheduled drugs was strongly restricted (i.e., initially limited to a specified pharmacy 
for an individual patient) (Norwegian Board of Health Supervision 1997;Norwegian 
Board of Health Supervision 1998).
The diagnoses of adult ADHD by the expert teams were primarily based on written 
information provided by local specialists (psychiatrist or clinical psychologist) 
26 MBD minimal brain disorder or dysfunction
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responsible for the assessment of ADHD, as well as psychiatric comorbidity and 
substance use. Based on available empirical evidence the expert teames developed 
and launched clinical guidelines on assessment, diagnosis, and treatment of ADHD 
in adults. The diagnostic assessment was primarily based on the ICD-10-DCR27 for 
hyperkinetic disorder (World Health Organization 1993), which is the official 
diagnostic system used in Norway. In accordance with National Health Authorities, 
two adjustments referring to the conceptualization of ADHD in the DSM-IV 
(American Psychiatric Association 1994) were made: first, acceptance of the 
primarily inattentive subtype of ADHD as a diagnostic option, and second allowing 
the presence of comorbid psychiatric disorders as long as the diagnostic criteria for 
ADHD were fulfilled and the symptoms did not occur exclusively during the course 
of a comorbid psychiatric condition. The reasons for these adjustments were the 
necessity to have assessment procedures that were in line with international 
diagnostic standards on adult ADHD.
Treatment with stimulant medication of adults provided by local specialists 
(psychiatrist or general practitioner) could only be started when 1) the diagnosis of 
ADHD was confirmed; 2) safety was secured with respect to medical and psychiatric 
concerns (e.g. blood pressure, current substance use); and 3) health authorities had 
licensed its use (Norwegian Board of Health Supervision 1998).
The procedures for the expert teams have been summarized in two main reports 
(Aanonsen et al. 2000;Aanonsen et al. 2004), and one supplemental report 
(Aanonsen et al. 2005) to the National Health Authorities. From October 1997 to 
August 2003, nationwide a total of 2516 applications had been received (Aanonsen et 
al. 2004). Among these, in 662 cases (24.7 %) the submitted documentation was 
lacking substantial information, and no diagnostic conclusion could be made. In 182 
cases (7.2 %) the expert teams advised against either the diagnosis of ADHD or 
treatment with stimulant medication. Finally, in 1712 cases (68.1 %) the expert teams 
approved the diagnosis of adult ADHD and recommended treatment with stimulant 
medication. By august 2003, a total of 262 adults with ADHD (15.3 % of the 1712 
cases) were registred to have been treated with stimulant medication for 24 months 
or more (Aanonsen et al. 2004).
27 DCR diagnostic criteria for research
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In spring 2005 the system with regional expert teams was replaced by National 
guidelines for diagnoses and treatment of ADHD (The Norwegian Directorate of 
Health 2007). Simultaneously, pharmacological treatment of adults with ADHD with 
stimulant medication was permitted on a more general matter (The Norwegian 
Directorate of Health 2007). Long-term data on a large number of adults with ADHD 
that had been collected by the regional expert team for South-Eastern Norway from 
August 2003 to May 2005 had not been analyzed yet, and constituted by this one of 
the starting points for the thesis.
3.2 Overview of investigations included in the thesis
In Table 2 a brief overview of the two studies included in the thesis (SIBBE and Fifty
Plus) is presented.
Table 2. Overview of studies included
Variables SIBBE* Fifty Plus
Year of data collection 2008-2009 2010
Eligible, n 1080# 251
Response rate n, % 376 (34.8) 166 (66.1)
Included n, % 368 (34.1) 149 (59.4)
Age, mean ± SD28, years 36.5±10.8 55.8±4.4
*SIBBE= Studie om iverksatt behandling, behandlingsforløp og effektvurdering (Study on initiated 
treatment, treatment course and treatment evaluation)
# 16 reported dead at follow-up, and the number of eligible participants has been adjusted to 1080
3.3 The SIBBE study
SIBBE stands as an acronym in Norwegian for “Studie om iverksatt behandling, 
behandlingsforløp og effektvurdering”, and is in English translated to “Study on 
initiated treatment, treatment course and treatment evaluation”. The SIBBE study was 
designed as a two-step questionnaire survey, where adults with ADHD who agreed to 
participate in the follow-up study were asked for permission to send a survey to the 
physician responsible for the treatment of ADHD.
28 SD standard deviation
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3.3.1 Sample of the SIBBE study
Eligible for the SIBBE study were 1096 adults from South-East Norway with a 
confirmed diagnosis of ADHD by the regional expert team for South-East Norway, 
and a confirmed consent of treatment with stimulant medication from august 2003 to 
spring 2005. These adults with ADHD had not been included in earlier reports by the 
expert teams (Aanonsen et al. 2000;Aanonsen et al. 2004). At follow-up, 16 persons 
were reported dead. We were unable to investigate the cause of death in these cases.
In Figure 1 the study flow is presented (adapted from Paper I).
Figure 1. Study Flowchart*
 
 
  
 
           
 
                      
 
 
 
 
 
               
                 
 
 
 
 
 
 
 
 
 
 
 
 
aInsufficient information for 43 subjects
Abbreviations: ADHD=attention-deficit/hyperactivity disorder, F=female, M=male.
*adapted from Lensing et al Four-Year Outcome in Psychopharmacologically Treated Adults With Attention-
Deficit/Hyperactivity Disorder: A Questionnaire Survey J Clin Psychiatry 2013:74 (1):e87-e93.
We compared participants (N=368) with non-participants with available information 
(N=661). The analyses did not reveal statistically significant difference as to 
Eligible for inclusion:
N = 1096; F = 388, M = 708
Reported dead:
n = 16; F = 2, M = 14
Questionnaires sent:
n = 1080; F = 386, M = 694
Unanswered questionnaires:
n = 704; F = 221, M = 483
Eligible for non-consent analysisa:
n = 661; F = 208, M = 453
Questionnaires returned:
n = 376; F = 164, M = 212
Denied participation/
never started treatment/
missing information:
n = 8; F = 2, M = 6
Treatment with 
ADHD medication:
N = 368; F = 162; M = 206
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hyperactivity, impulsivity or inattention scores at baseline. Participants were older (at 
baseline mean age 31.6±10.7 vs29 28.8±10.1; T=-4.6, DF=1027, P<0.001), more 
often females (44.0 % vs 32.0 %; Ȥ2=16.2, DF=1, P<0.001), and had a slightly higher 
score on the SCL-90-R30 depression subscale at baseline (1.6±1.0 vs 1.5±0.9; T=2.1, 
DF=623, P<0.05) than non-participants. Scores on other subscales and the GSI31
showed no significant differences between participants and non-participants at 
baseline. Neither did self-reported ADHD impairment differ between groups.
Sample characteristics of the 368 adults with ADHD included in the SIBBE study are 
presented in Table 3 (adapted from Paper I).
29 VS versus
30 SCL-90-R Symptom Checklist 90-Revised
31 GSI global severity index
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Table 3. Population Characteristics of 368 Adults with ADHD at Baseline*
Population Characteristics Values
Age, mean ± SD, years 31.9 ± 10.7
Gender, n (%)
Females 162 (44.0)
Males 206 (56.0)
Highest educational level, n (%)
Junior high school 168 (45.7)
Senior high school 119 (32.3)
College/University 46 (12.5)
Missing 35 (9.5)
Civil status, n (%)
Single 190 (51.6)
Married/Cohabited 133 (36.2)
Missing 45 (12.2)
Employment, n (%)
Employed/under educationa 182 (49.4)
Unemployed/disability pensionb 157 (42.7)
Missing 29 (7.9)
Subtype ADHD diagnosis, n (%)
Combined 155 (42.1)
Predominantly Inattentive 132 (35.9)
Predominantly Hyperactive-Impulsive 22 (6.0)
Residual 28 (7.6)
Insecure subtype 31 (8.4)
Diagnosis of ADHD during childhood/adolescence, n (%) 87 (23.6)
One or more comorbid psychiatric disorders at baselinec, n (%) 224 (60.9)
Substance use 142 (38.6)
aUnder education: n=82 
bDisability pension: n=126
cExcluding Substance use; Most frequent comorbid psychiatric disorders: mood disorders (n=146); anxiety disorders 
(n=107); personality disorders (n=44); other psychiatric disorders (n=42)
Abbreviation: ADHD=attention deficit hyperactivity disorder
*adapted from Lensing et al Four-Year Outcome in Psychopharmacologically Treated Adults With Attention-
Deficit/Hyperactivity Disorder: A Questionnaire Survey J Clin Psychiatry 2013:74 (1):e87-e93.
3.3.2 Primary Care Physicians (PCPs)
Adults with ADHD who had agreed to participate in the SIBBE study were asked for 
permission to send a survey to the physician responsible for the treatment of ADHD. 
The vast majority of our sample of 368 adults with ADHD agreed to participate 
(n=305; 82.9 %). Participants were older (mean age at follow-up was 37.4±11.1 vs 
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32.8±8.9; T=3.6, DF=106.1, P=0.001), and more often female (88.3 % vs 78.6 %; 
Ȥ2=5.9, DF=1, P=0.015) compared to nonparticipants. Among the 305 participants, a 
majority of 274 (89.8 %) reported to be treated for ADHD by a PCP, whereas 31 
(10.2 %) reported to be treated for ADHD by a specialist. Reports by specialists did 
not differ substantially from those by PCPs, and have not been included in Paper II.
3.4 The Fifty Plus study
The aim of the Fifty Plus study was to investigate use and persistence of
pharmacotherapy, and to assess QoL32 in middle-aged and older adults with ADHD. 
The study has been carried out in collaboration with the Norwegian ADHD patient 
organization. The Norwegian ADHD patient organization was established in 1979 
and has nearly 10 000 members. The study was designed as an anonymous 
questionnaire survey among members of the patient organization with a registred 
diagnosis of ADHD, and aged fifty years and older. To secure anonymity the 
questionnaire was sent three times to the eligible sample by the patient organization.
3.4.1 Eligible sample of the Fifty Plus study
Altogether 251 members of the patient organization fulfilled the inclusion criteria 
(e.g., being fifty years of age and older, and registered with a diagnosis of ADHD). 
More than 50 % of the eligible sample was female (n=140; 55.8 %). The mean age 
was 55.5±4.8 years (range 50-80 years), and with no statistically significant 
difference as regards to gender. The majority (n=183, 72.9 %) was settled in the 
South-Eastern part of the country. According to Statistics Norway by 2013 more than 
55 % of the total Norwegian population was settled in the South-Eastern part of the 
country (Statistics Norway 2013).
3.4.2 Reference samples in the Fifty Plus study
Population samples from Denmark on quality of life and Norway on satisfaction with 
life served as reference samples (Paper IV).
32 QoL quality of life
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We used the EQ-5D33 (The EuroQol Group 1990) as a measurement of HRQoL34.
Unfortunately, population data for this instrument are not available for Norway yet. 
Therefore recently published Danish EQ-5D data served as a reference sample in our 
study (Sorensen et al. 2009). The Danish reference sample comprised quality of life 
data from three population health surveys on 15.700 individuals aged 20-79 years 
(Sorensen et al. 2009). In our study the reference sample was limited to individuals 
in the age groups 50-59 years (n=3162; 50.8 % females) and 60-69 years (n=2121; 
52.3 % females). Studies have shown that the Nordic countries are quite similar with 
respect to well-developed health and welfare politics (Wahlbeck et al. 2011).
Population data for satisfaction with life measured with the SWLS35 (Diener et al. 
1985) were adapted from the NorLAG36 study. NorLAG includes data from 2003-
2007 on more than 3.500 individuals 40 years of age and older as well as 15.000 
individuals aged 18 years and older from the Norwegian study of life course, 
generation and gender, which in 2007 was merged with the original NorLAG study 
(The Norwegian study on life course ageing and generation (NorLAG) 2011).
3.5 Measurements
3.5.1 Diagnostic assessments in the SIBBE study
Assessment of the diagnoses hyperkinetic disorder and ADHD, Combined Type was 
based on ICD-10-DCR (World Health Organization 1993) and DSM-IV/DSM-IV-
TR (American Psychiatric Association 1994;American Psychiatric Association 
2000), respectively. For subjects with primarily inattention problems, criteria for 
ADHD Predominantly Inattentive Subtype in DSM-IV were applied. Baseline 
diagnostic conclusions were reassessed by checking the inter-rater reliability for two 
independent raters of records from 54 randomly selected study subjects. Cohen’s 
Kappa values for ADHD combined and predominantly inattentive subtypes were .94 
and .87, respectively.
33 EQ-5D EuroQol 5D
34 HRQoL health related quality of life
35 SWLS Satisfaction With Life Scale
36 NorLAG Norwegian study on life course, ageing and generation
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3.5.2 Questionnaires in the SIBBE and the Fifty Plus study
Initially, questionnaire items were evolved from baseline characteristics, research 
questions, and structured instruments (see Table 4 for detailed information). We used 
focus- and expert groups during the development and testing of the questionnaires.
Table 4. Overview of main instruments in SIBBE* and Fifty Plus
Instruments SIBBE Fifty Plus
General Adult ADD Questionnaire x
Adult ADHD Self Report Scale (ASRS) Symptom Checklist x
Adult ADHD Self-Report Scale (ASRS v1.1) - Screener x x
Symptom Checklist 90-Revised (SCL-90-R) x
Mental Health Index-5 (MHI-5) x
Sheehan Disability Scale (SDS) x
Euroqol-5D (EQ-5D) x
Satisfaction with Life Scale (SWLS) x
*SIBBE= Studie om iverksatt behandling, behandlingsforløp og effektvurdering (Study on initiated 
treatment, treatment course and treatment evaluation) 
In the SIBBE study adults with ADHD also were asked to report on 21 questions 
concerning sociodemographic variables including educational and occupational 
level, pharmacological treatment, misuse of ADHD medication, nonpharmacological 
and psychosocial treatment for ADHD, treatment outcome and evaluation as well as 
somatic and psychiatric comorbidity.
Participating PCPs37 and psychiatrists, responsible for treatment of ADHD, answered 
nine questions about ADHD treatment that were identical with the patient 
questionnaire (current treatment with ADHD medication, prescribed daily dosage, 
reasons for stopping treatment, and nonpharmacological treatment for ADHD). 
Physicians were asked about mistrust with respect to patients’ use of prescribed 
ADHD medication. Information about treatment of substance use, and treatment with 
medication other than for ADHD were asked for. Physicians also reported on side 
effects of treatment with ADHD medication that had lasted longer than for two 
weeks, including psychosis, suicidal thoughts, and suicidal acts. Finally, they were 
37 PCP primary care physician 
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asked to rate the current functioning of the adult with ADHD on a five-point scale 
from 1 (seriously impaired) to 5 (very good).
Participants in the Fifty Plus study were asked to answer 35 additional questions 
concerning sociodemographic factors including educational and occupational level, 
work motivation and capacity, age when diagnosed with ADHD, pharmacological 
treatment for ADHD, nonpharmacological treatment for ADHD, substance use, 
comorbidity, life satisfaction, loneliness, and mastering of every day life. For reasons 
of comparison, the majority of these items were adapted from the NorLAG38
protocol (Solem 2003).
(See Appendix for the Norwegian versions of the questionnaires used in the SIBBE
and the Fifty Plus study, respectively).
3.5.3 ADHD symptom scores
3.5.3.1 Baseline assessment in the SIBBE study
The General Adult ADD Questionnaire (Amen 1997) is a self-report instrument 
designed to assess childhood ADHD history, current ADHD symptomatology and 
associated features. The original form consists of 77 questions. In 2000 the expert 
teams introduced a comprised version with 29 questions yielding five subscales 
(inattention, restlessness, impulsivity, organization difficulties and procrastination). 
Items are scored on a five-point scale from 0 (never) to 4 (very frequently). From 
1997 to 2003 primarily this instrument was used to assess baseline ADHD 
symptomatology. The instrument was translated into Norwegian by the expert teams, 
but has never been officially validated in Norway.
A pilot version of the WHO Adult ADHD Self-Report Scale (ASRS) Symptom 
Checklist (World Health Organization and Workgroup on Adult ADHD 2003) 
replaced the General Adult ADD Questionnaire from 2004. The ASRS is a self-report 
instrument designed to assess current ADHD symptoms in adults. Basically, the 18 
items of the ASRS are the DSM-IV criteria for ADHD, but have been slightly 
modified to fit for adults. The instrument consists of 9 items assessing inattention 
(part A), and 9 items assessing hyperactivity and impulsivity (part B). Items are 
38 NorLAG Norwegian study of life course, ageing and generation
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scored on a five-point scale from 0 (never) to 4 (very often), giving a sum score 
ranging from 0-54. In the pilot version the following scoring recommendation is 
given; 0-16 points: the patient is not likely to have ADHD in adulthood; 17-23
points: the patient is likely to have ADHD; and 24 points or more on either part A or 
B: the patient is highly likely to have ADHD in adulthood. The instrument was 
translated into Norwegian by the expert teams, but has never been officially validated 
in Norway. The wording of the items in the pilot version is not substantially different 
from the ASRS Self-Report Scale (ASRS v1.1) Symptom Checklist (Adler et al. 
2006a;Kessler et al. 2005b), which has been used extensively in clinical practice and 
research.
3.5.3.2 Follow-up assessment in the SIBBE and the Fifty Plus study
At follow-up, current ADHD symptoms were assessed with the WHO Adult ADHD 
Self-Report Scale (ASRS v1.1)–Screener (Kessler et al. 2007). The ASRS Screener 
consists of six of the eighteen questions of the WHO ASRS Self-Report Scale 
(ASRS v1.1) Symptom Checklist that were found to be most predictive of symptoms
consistent with ADHD. Four of the six items are measuring inattention, and two 
items are measuring hyperactivity/impulsivity. Symptom frequency is rated on a 
five-point scale ranging from 0 (never) to 4 (very often). Scores were summed with a 
cutoff score of 14 (Taylor et al. 2011). The ASRS Self-Report Scale (ASRS v1.1) 
Symptom Checklist has not been officially validated in Norway. The Norwegian 
Directorate of Health has been responsible for the translation of the official 
Norwegian version of the ASRS v1.1, and ensured that this was carried out in line 
with the specifications by the copy right holders (i.e., forward and backward 
translation, test period and wording adjustment by experts). The ASRS v1.1 has been 
used both in clinical practice and research (Halmoy et al. 2010;Halmøy 
2011;Rasmussen et al. 2001).
3.5.4 Mental health 
3.5.4.1 Baseline assessment in the SIBBE study
The Symptom Checklist 90-Revised (SCL-90-R) (Degoratis 1994) is a screening 
instrument designed to measure general psychiatric symptomatology. The SCL-90-R
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consists of 90 statements scored on a five-point scale from 0 (not at all) to 4 (very 
much). Scoring yields 9 subscales (somatization, obsessive-compulsive, depression, 
anxiety, phobic anxiety, hostility, interpersonal sensitivity, paranoid ideation, and 
psychoticism) and a Global Severity Index (GSI), which is the mean of all 
statements. Higher scores indicate more symptomatic distress. The validated 
Norwegian version of the SCL-90-R (Vassend et al. 1992) was used in the study.
3.5.4.2 Follow-up assessment in the SIBBE study
The Mental Health Index-5 (MHI-5) is one of eight subscales of the Short Form 36®
(Ware, Jr. et al. 2000). The five items of the MHI-5 are “Have you ever been a 
nervous person?”, “Have you felt so down in the dumps that nothing could cheer you 
up?”, “Have you felt calm and peaceful?”, “Have you felt downhearted and blue?”, 
and “`Have you been a happy person?”. Items are scored on six possible alternatives 
from “all of the time” to “not at all” with a score between 5 and 30, which is 
transformed linearly to a scale from 0 to 100. Higher scores indicate better mental 
health. The SF-36 has been validated for the Norwegian population (Loge and Kaasa 
1998).
The Sheehan Disability Scale (SDS) (Leon et al. 1997) is designed to assess mental-
health related impairment. The SDS consists of three self-rated items regarding work, 
social, and family impairment because of emotional symptoms: “To what extent have 
emotional symptoms disturbed your (work, social, family) life in the past week?” 
The items are rated from 0 to 11, with 0 (not at all), 13 (mildly), 46 (moderately), 
79 (markedly), 10 (extremely), and 11 (not applicable). An SDS total score of t5
has been found to be associated with increased risk of mental health-related 
functional impairments. The Sheehan Disability Scale has not been validated for the 
Norwegian population. On the other hand has the scale been used in several research 
studies (Irgens et al. 2012;Tjemsland and Soreide 2001).
3.5.5 Quality of Life assessment in the Fifty Plus study
The EQ-5D is a generic standardized health-related quality of life self-report 
instrument developed by the EuroQol Group (The EuroQol Group 1990). The EQ-5D 
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consists of five descriptive dimensions (mobility, self-care, usual activity, 
pain/discomfort and anxiety/depression) and a visual analogue “thermometer” scale 
(EQ-VAS). On each of the five dimensions subjects are asked to judge their current 
health state on one of three possible levels: “no”, “some” or “extreme” problems, 
which is scored 1, 2, and 3, respectively. On the EQ-VAS subjects are asked to 
indicate current health condition on a scale from 0 (worst imaginable health state) to 
100 (best imaginable health state). Recently, the EuroQol Group gave new 
definitions for the EQ-5D nomenclature and changed the designation of the version 
used in our study to EQ-5D-3L (EuroQol Group 2013a). For the sake of clarity the 
former abbreviation EQ-5D will be used throughout the thesis. The instrument has 
been translated into Norwegian (EuroQol Group 2013b). Norwegian population data 
are not available yet. Therefore, recently published Danish EQ-5D data were used as 
a reference sample in the Fifty Plus study (Sorensen et al. 2009).
The Satisfaction with Life Scale (SWLS) (Diener et al. 1985) is a five-item self-
report questionnaire measuring the satisfaction with one’s life as a whole. The five 
items are: “In most ways my life is close to my ideal,” “The conditions of my life are 
excellent,” “I am satisfied with my life,” “So far I have gotten the important things I 
want in my life” and “If I could live my life over, I would change almost nothing.” 
The original version of this instrument uses a seven-point response scale. We used a 
five-point response scale that ranged from 1 (totally disagree) to 5 (totally agree), 
giving total scores that ranged from 5 (extremely dissatisfied) to 25 (highly satisfied). 
With the seven-point scale, a total score of 20 is defined as neutral (Diener 2012), 
whereas we set the equivalent score on the five-point scale at 15. The SWLS has 
been translated into Norwegian. Although so far no Norwegian validation data are 
available, the reliability and validity of the SWLS has been proven by extensive 
research (Vittersø 2009).
ADHD-related improvement during psychopharmacological treatment was assessed 
with a self-reported improvement question (SRIQ39) (ie, “Have you experienced 
improvement during treatment for ADHD?”). The question is scored on a ten-point 
visual analog scale from 0 (no) to 1-3 (little), 4-6 (moderate), 7-9 (much) to 10 (very 
great) improvement. The question has not been used previously in research.
39 SRIQ self-reported improvement question
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3.6 Statistics
In the descriptive part of the studies, chi-square statistics were used when assessing 
pairwise associations between categorical variables. Associations between binary and 
continuous variables were analyzed with independent samples t-test or one-way 
ANOVA. Scheffé’s post-hoc analysis was performed to assess group differences 
whenever appropriate. Associations between continuous variables were analyzed 
using Pearson correlation coefficients, whereas Spearman rho was used to calculate 
correlation coefficients between categorical and continuous variables. Linear and 
binary logistic regression analyses were performed to identify factors associated with 
better outcome.
In the SIBBE study (Papers I and II) the level of significance was 5 %. To increase 
the probability to report true findings the level of significance was set to 1 % in the 
anonymously performed Fifty Plus study (Papers III and IV).
In Paper I (SIBBE study) Cohen’s Kappa was used to estimate the inter-rater 
reliability for diagnostic categories.
In Paper II (SIBBE study) the kappa statistics was used to assess agreement between 
PCPs’ and patients’ reports on selected variables. A kappa-value of 1 indicates 
complete agreement, whereas a kappa-value of 0 indicates that the agreement is not 
more than expected by chance (Kirkwood and Sterne 2011). According to Landis et 
al. (1977), kappa-values greater than .81 represent an almost perfect agreement, 
values between .61-.80 substantial agreement, values between .41-.60 moderate 
agreement, and values of .40 and below represent fair-to-poor agreement (Landis and 
Koch 1977). Standard errors for kappa-values were calculated using bootstrapping. 
Variables with empty cells or where one cell accounted for more than 90 % of the 
distribution were excluded from the analysis. PCP-patient agreement on continuous 
variables was analyzed with a paired samples t-test.
In Paper IV (Fifty Plus study) the percentages in the Danish EQ-5D sample were 
adjusted for the age and gender distribution of the ADHD group as recommended by 
Hjermstad (Hjermstad et al. 1998). A one-sample non-parametric binominal test was 
then used to analyze for statistically significant differences.
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Statistical analyses were performed with the predictive analytic software PASW 
Statistics 18.0 for Windows (IBM, Armonk, NY). The PhD candidate under 
supervision by a statistician did all statistical analyses.
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4. ETHICS
4.1 The SIBBE study
The SIBBE study was approved by the Regional Ethic Committee for South-East 
Norway and the Norwegian Data Inspectorate. An informed consent based on 
detailed written information in line with research ethical standards was obtained from 
all participants in the follow-up part of the SIBBE study. Those, who agreed to 
participate in the patient-physician part of the study, had to provide updated 
information about the physician responsible for the treatment for ADHD. The 
physician questionnaire contained detailed information about the study, and 
information about the patients’ agreement to participate.
A postal questionnaire was sent the eligible sample of adults with ADHD. Based on 
previous research a pre-notification (a lottery-ticket of a value of 25 Norwegian 
Kroner) was given in the patient questionnaire (Edwards et al. 2007). One reminder, 
without any further pre-notifications, was sent. Participating physicians could order a
scientific book about ADHD on request as compensation for the time they had used 
with the questionnaire. 
Questionnaires could be answered either by postal return or by choosing a secured 
web-based solution with a personal code.
4.2 The Fifty Plus study
The Data Protection Officer at Oslo University Hospital approved the Fifty Plus 
study. The Regional Ethic Committee for South-East Norway had concluded that this 
was satisfactory. The study was anonymous, and therefore no further consent was 
required.
The questionnaire was sent to the eligible sample by the patient organization.
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5. RESULTS
5.1 Paper I
Four-year outcome in psychopharmacologically treated adults with Attention-
Deficit/Hyperactivity Disorder: a questionnaire survey.
Paper I is a cross-sectional questionnaire survey that was performed among adults 
with ADHD, diagnosed according to ICD-10/DSM-IV and approved for 
pharmacotherapy during 2003-2005. Of an eligible number of 1080, 371 subjects 
(34.4 %) agreed to participate, and 368 of these reported having ever been treated 
with ADHD medication. Baseline characteristics and self-reported outcome was 
studied by duration of psychopharmacological treatment. Primary outcome measures 
were the ASRS-Screener (ADHD symptoms) and the MHI-5 (mental health). Based 
on cutoff scores for these instruments, two groups (favorable outcome versus others) 
were created to study possible predictors of outcome status.
We found a high attrition rate, but self-reported baseline ADHD symptoms and 
impairment did not differ between participants and non-participants. The mean 
observation time was 4.5 (3.5-6.0) years, and the mean age at follow-up was 36.5 
years. Altogether 270 participants (73.4 %) had been treated for more than 24 
months. They reported better outcome on all measures compared to those treated for 
less than 24 months (mean values: ASRS-Screener: 12.8 vs 15.3; MHI-5: 63.7 vs 
56.7). We found that the favorable outcome group consisted of 79 participants (21.5 
%). Among sample characteristics comorbidity at baseline predicted poorer outcome.
5.2 Paper II
Adults with ADHD: use and misuse of stimulant medication as reported by 
patients and their primary care physicians.
Paper II is a cross-sectional survey that was administered among adults with ADHD 
and the primary care physicians responsible for their ADHD treatment. The kappa 
statistics assessed physicianpatient agreement on ADHD treatment variables. The 
eligible sample consisted of 274 patients with confirmed current or previous 
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psychopharmacological treatment for ADHD and the physicians responsible for their 
treatment.
We received 159 questionnaires (58.0 %) with sufficient information from both 
sources. There were no significant differences between participants and 
nonparticipants (N=115) on ADHD sample characteristics. Participants’ mean age 
was 37.6 years, and 75 of participants (47.2 %) were female. We found high 
agreement for current pharmacological treatment of ADHD, current and last ADHD 
drug prescription, treatment of substance use, and misuse of stimulant medication. 
Agreement for nonpharmacological treatment of ADHD and treatment termination 
because of side effects was low. A minority of participants from both sources 
reported misuse of stimulant medication. There was a moderate correlation between 
the physicians’ clinical judgment and patients’ self-report on current functioning. We 
concluded that primary care physicians could safely undertake pharmacological 
treatment of adults with ADHD.
5.3 Paper III
Psychopharmacological treatment of Attention-Deficit/Hyperactivity Disorder 
in adults aged 50+: an empirical study.
Paper III is a cross sectional anonymous survey that was administered to adults with 
ADHD 50 years of age and older. Eligible for the study were 251 members of a 
National ADHD patient organization, and 149 (59.4 %) with sufficient information 
were included. Participants on medication for ADHD were compared with those not 
on medications.
Mean age of participants was 55.8 years, and mean age when diagnosed with ADHD 
was 50.3 years. We found that 95 participants (63.8 %) reported current
psychopharmacological treatment for ADHD, 36 (24.2 %) had stopped 
psychopharmacological treatment, and 18 (12.0 %) were psychopharmacologically 
treatment naive for ADHD. Those currently being treated psychopharmacologically 
for ADHD reported significantly improved attention relative to the two currently 
nonmedicated groups (p<0.01). Among examined sample characteristics (including 
current psychopharmacological treatment for ADHD), employment was associated 
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with a better outcome (OR40=3.3, p=0.006). We concluded that the majority of adults 
aged 50+ with ADHD in this study reported regular pharmacotherapy for ADHD. 
Participants currently receiving psychopharmacological treatment for ADHD 
reported better attention than those not receiving pharmacotherapy. Employment was 
associated with more favorable outcomes.
5.4 Paper IV
Quality of life in adults aged 50+ with ADHD.
Paper IV is a cross sectional anonymous survey that was administered to adults with 
ADHD 50 years of age and older. Eligible for the study were 251 members of a 
National ADHD patient organization, and 148 (59.0 %) with sufficient information 
were included. Quality of life was assessed with EuroQol (EQ-5D) and the 
Satisfaction with Life Scale (SWLS). Age-matched Danish and Norwegian 
population samples served as reference groups.
We found that the mean age of participants was 55.7 years, and the mean age when 
diagnosed with ADHD was 50.2 years. The mean ASRS-Screener score was 15.2. 
Adults with ADHD reported significantly reduced health-related quality of life and 
reduced satisfaction with life compared to population norms. Non-employment and 
severe ADHD were associated with poor quality of life. We concluded that the 
negative impact of ADHD persists into late adulthood.
40 OR odds ratio
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6. DISCUSSION
6.1 Discussion of the main findings
6.1.1 Use and persistence of psychopharmacological treatment for ADHD
Despite an observation time of more than four to five years, the majority of our 
adults with ADHD (more than 60 %) reported current pharmacological treatment for 
ADHD. The findings were strengthened by the high levels of agreement between 
reports from PCPs41 and those from their patients on current and terminated 
pharmacotherapy for ADHD.
One of the main challenges in treatment is that “drugs don’t work in patients who 
don’t take them” (Osterberg and Blaschke 2005). For instance in psychiatry, 
nonadherence has been found to be associated with poorer outcomes, including 
increased rates of hospital admissions and mortality (Chapman and Horne 2013). In 
the field of ADHD recent investigations showed that when treated and untreated 
samples were compared, improved long-term outcomes for those who had been 
treated were found (Arnold et al. 2013;Shaw et al. 2012).
Research has shown that treatment persistence typically one year after treatment start 
for ADHD is challenged by critical viewpoints to treatment and increased 
forgetfulness (Eichlseder 1985). Difficulties in adherence with drug treatment over 
time have been reported frequently in adults with ADHD (Adler and Nierenberg 
2010;Sitholey et al. 2010). Chart review studies (McCarthy et al. 2009;Olfson et al. 
2007;Perwien et al. 2004), and open label safety and efficacy studies (Adler et al. 
2008;Adler et al. 2011;Biederman et al. 2005b) showed that most adults used their 
ADHD medication for less than six months.
Persistence of psychopharmacological treatment for ADHD generally is less 
consistent in clinical than research settings (Miller et al. 2004;Naidoo et al. 2013). 
This is in line with findings from other fields in medicine where treatment 
persistence has been shown often to decline dramatically over time (Osterberg and 
Blaschke 2005). Although there is a strong scientific evidence for the efficacy of 
psychopharmacological treatment of ADHD in adults (Fredriksen et al. 2013;Huang 
41 PCP primary care physician
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and Tsai 2011;Kooij et al. 2010;Retz et al. 2011;Santosh et al. 2011;Wilens et al. 
2011), high rates of non-adherence (64 % to 80 %) five years after treatment start in 
ADHD samples have been reported (Adler and Nierenberg 2010;Winterstein et al. 
2008). Interestingly, a recent European chart review study reported rates of treatment 
presistence in line with our findings (The National Board of Health and Welfare 
(Socialstyrelsen) 2012).
Several factors may have contributed to our results. One of these probably has been 
access to improved dosing schedules, e.g., single dosing once a day that has been 
shown to contribute to increased adherence (Osterberg and Blaschke 2005). Among 
participants in the SIBBE study who reported current psychopharmacological 
treatment for ADHD, the majority used long-acting MPH42. They reported better 
treatment adherence than the group treated with short-acting methylphenidate. 
Similar results have been published recently where increased use of extended-release 
formulations of MPH predicted longer treatment duration in a sample of adults with 
ADHD and high degree of comorbidity (Torgersen et al. 2012). Also, a recent chart 
study from Denmark found that adults aged 50+ with ADHD were more adherent to 
pharmacological treatment than their younger counterparts (Pottegard et al. 2013).
The physician-patient relationship has been identified to be another important factor 
for long-term treatment adherence (Chapman and Horne 2013;Osterberg and 
Blaschke 2005;Vermeire et al. 2001). We found high levels of agreement for current 
pharmacological treatment of ADHD, current and last ADHD drug prescription, 
treatment of substance use, and misuse of stimulant medication between PCPs and 
their patients. According to national guidelines, psychopharmacological treatment of 
adults with ADHD included in our study had to be started by local specialists 
(psychiatrists or general practitioners) (Norwegian Board of Health Supervision 
1998;The Norwegian Directorate of Health 2007). Initial findings from the MTA43
study after 14 months of treatment showed that treatment by specialists was superior 
to community treatment (The MTA Cooperative Group 1999a), and it recently has 
been suggested that “the techniques for medication initiation used by specialists may 
be one reason that specialist care leads to increased duration of use over time” in 
treatment of ADHD (Charach and Fernandez 2013). A qualitative study on 
42 MPH methylphenidate
43 MTA Multimodal Treatment Study of Children with ADHD
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impairment, service provision and clinical management of adult ADHD underlined 
the importance of qualified guidance by a specialist on treatment adjustments and 
follow-up for adherence (Matheson et al. 2013).
Reimbursement and distance to health care facilities are other important aspects 
associated with increased adherence to treatment (Osterberg and Blaschke 
2005;Sabate 2003). Nordic welfare systems are characterized by access to equal 
treatment conditions, the availability of specialists throughout the country and state 
payment for necessary medical treatments (Wahlbeck et al. 2011;Zoega et al. 2011).
Although we found high rates of use and persistence of treatment over time, we did 
not assess therapy bouts in particular. Studies have revealed that up to 45 % of 
patients with ADHD had one or more therapy bouts during treatment for the disorder 
(Bahmanyar et al. 2013;Miller et al. 2004).
6.1.2 ADHD symptomatology and current functioning
We found inconsistent results with respect to ADHD symptomatology. On one hand, 
adults currently treated with ADHD medication in the SIBBE study (the younger 
adult ADHD sample) reported significantly lower ADHD symptomatology when 
measured with the ASRS Screener compared to those unmedicated for the disorder. 
On the other hand, in the Fifty Plus study no statically significant differences in the 
ASRS Screener mean scores between treatment groups were found, although those 
currently treated with ADHD medication reported significantly better attention than 
those unmedicated for the disorder. The current functioning in both samples was 
significantly decreased when compared to normal controls and population norms. 
Only a minority of participants reported levels of ADHD symptomatology and 
current functioning in line with remission.
Our findings of a significant difference between treatment groups for inattention but 
not for hyperactivity and impulsivity are in line with previous research (Biederman et 
al. 2000;Faraone and Glatt 2010;Wilens et al. 2002;Willcutt et al. 2012). The 
inconsistent results with respect to the ASRS Screener mean scores need some 
further considerations.
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In the SIBBE study more than 55 % in the currently treated group had an ASRS 
Screener score below cutoff, whereas the corresponding number in the off-
medication group was 35 %. These results were well in line with reports from short-
term efficacy studies of ADHD pharmacotherapy on core symptoms in adults 
(Faraone et al. 2004;Fredriksen et al. 2013;Santosh et al. 2011;Wilens et al. 2011). 
Open label studies of use of stimulant medication in adolescents and adults with 
ADHD lasting up to 24 months have, despite high attrition rates, underpinned these 
findings (Adler et al. 2011;Biederman et al. 2005b;Buitelaar et al. 2011b;Wilens et 
al. 2005). Similar results of treatment with stimulant medication on ADHD core 
symptoms have been reported in some longer lasting follow-up studies (Bejerot et al. 
2010;Torgersen et al. 2012;Wender et al. 2011). Neurobiological research showed 
that increase of dopamine enhancement in specific brain areas was associated with 
response to long-term treatment with MPH (Volkow et al. 2012). This may 
secondary be followed by an upregulation of dopamine transporters, and can result in 
further decreases of dopaminergic signaling when unmedicated for shorter periods of 
time (Wang et al. 2013). Thus, based on these neurobiological research findings one 
could argue for continuous pharmacotherapy over time for the disorder.
In the Fifty Plus study the mean ASRS Screener scores for all three-treatment groups 
were above the cutoff of 14, and no statistically significant differences were observed 
between groups. The percentage of participants who had an ASRS Screener score 
below the cutoff (34 %) was much lower than in our younger sample of adults 
(SIBBE study). Overall, our results did not comport with a previous report of 
treatment outcomes on core symptoms being similar to those seen in younger adults 
with ADHD (Manor et al. 2011).
One possible explanation could be related to the instrument itself. The ASRS 
Screener was originally developed to detect symptoms of ADHD in adults aged 18–
44 years (Kessler et al. 2005b). To the best of our knowledge, the applicability of this 
instrument in adults older than 44 years of age has yet to be validated.
Another explanation, somewhat contrary to our findings from the younger sample of 
adults with ADHD, could be that there is no significant long-term advantage of 
pharmacotherapy for ADHD relative to other therapies or no therapy in middle-aged 
and older adults. Interestingly, long-term follow-up of children with ADHD showed 
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improvement on ADHD and associated symptoms from baseline, with initial 
differences in outcomes between treatment strategies (such as pharmacotherapy and 
behavior modification) disappearing over time, as shown in the Multimodal 
Treatment Study of Children with ADHD (MTA study) (Molina et al. 2009).
Age-related changes in the dopaminergic system, such as the decreased availability 
of dopamine transporters and dopamine receptors when getting older, must also be 
seen as a possible explanation. This downregulation of the dopamine system may 
reduce the efficacy of treatment with stimulant medications (Volkow and Swanson 
2003). Our sample of adults’ aged 50+ with ADHD consisted of more women than 
men. Research has shown that after menopause the availability of dopamine 
receptors is higher than in men at the same age (Kaasinen et al. 2002). Hence, a more 
balanced gender distribution probably would have revealed an even worse outcome 
for those currently receiving medication.
The timing of treatment onset could be a possible explanation as well, as those who 
are diagnosed with ADHD later in life do not respond as strongly to pharmacological 
treatment as those who are diagnosed earlier (Dalsgaard et al. 2013;Gjervan et al. 
2012a;Matheson et al. 2013).
We found that adults with ADHD in different age groups reported significantly 
decreased current functioning when compared to normal controls. Early 
investigations in the field of ADHD showed that hyperactives who were considered 
to be clearly drug responders even after treatment with stimulant medication for 
more than three years in young adulthood functioned significantly worse than their 
matched controls. Rather, their level of functioning in most domains was similar to 
untreated hyperactives (Hechtman et al. 1984a). Both efficacy and long-term 
effectiveness studies (e.g., MTA-study) have revealed only small improvements of 
psychopharmacological treatment beyond the core symptoms of the disorder (Brown 
et al. 2005;Buitelaar et al. 2011b;Case 2011;Durell et al. 2013;Langberg and Becker 
2012;Marcus and Durkin 2011;Molina et al. 2009).
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PCPs in our study rated the current functioning of their ADHD patients as neither 
impaired nor good. These adults with ADHD reported elevated SDS44 scores after 
more than 4.5 years of follow-up, which also has been found in a four-year long-
term, open label study of adults with ADHD treated with atomoxetine (Adler et al. 
2008).
We found an association between symptoms of inattention and reduced function in 
everyday activities. In adults with ADHD symptoms of inattention have been found 
strongly associated with functional impairment and occupational outcome (Gjervan 
et al. 2012a;Szuromi et al. 2013;Weiss et al. 2010). Whereas some reported 
symptoms of impulsivity to have a strong impact on functional impairment (Szuromi 
et al. 2013), others found that the relationship between ADHD inattentiveness and 
occupational outcome was completely moderated by emotionional distress and 
impairment in social functioning (Gjervan et al. 2013).
In our study only a minority of participants (21.5% in the SIBBE study, and 19.1% in 
the Fifty Plus study) reported a level of ADHD symptomatology and current 
functioning that could be classified as remission, i.e., loss of diagnostic status and 
optimal functioning as a proposed goal for treatment (Ramos-Quiroga and Casas 
2011;Steele et al. 2006;Weiss et al. 2006). Unfortunately, these results correspond 
well with similar rates of remission from follow-up studies (Miller et al. 2004;Steele 
et al. 2006), and underline the persistent negative impact of the disorder.
6.1.3 Quality of Life (QoL) in adults with ADHD
In our study adults with ADHD in different age groups reported significantly reduced 
quality of and satisfaction with life when compared to population norms. Ongoing 
psychopharmacological treatment did not result in statistically significant 
improvements in current functioning and satisfaction with life when compared to 
unmedicated groups.
Assessment of QoL was performed several years after a diagnostic conclusion of 
ADHD, and in most cases after a longer period of time with psychopharmacological 
treatment for ADHD with stimulant medication. The results differ somewhat from 
44 SDS Sheehan Disability Scale
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previous reports of a positive short-term impact of medication on QoL in younger 
adults with ADHD who primarily had been treated with atomoxetine (Adler et al. 
2006b;Agarwal et al. 2012;Coghill 2010;Weiss et al. 2010). Recent research showed 
that childhood ADHD, even in those who no longer meet criteria for the disorder, 
was associated with educational, occupational, and economic disadvantages when 
compared to controls (Klein et al. 2012). Increased awareness of the persistence of 
ADHD into adulthood might be a risk for stigmatization related to ADHD with 
impact on QoL and life satisfaction (Fuermaier et al. 2012;Lebowitz 2013;Mueller et 
al. 2012). On the other hand, it also has been reported that some can achieve 
improvement of QoL despite an unchanged symptom profile (Bastiaansen et al. 
2005).
Our results showing increased problems with physical activities in middle-aged and 
older adults with ADHD correspond well with a recent review that found ADHD to 
be associated with worse physical outcomes (Nigg 2012). Studies of middle-aged 
and older adults showed that ADHD symptomatology was associated with increased 
health problems (Bernardi et al. 2012;Das et al. 2012;Guldberg-Kjar and Johansson 
2009;Manor et al. 2011;Semeijn et al. 2013a). Adults with ADHD in different age 
groups reported significantly higher rates of asthma, migraine headaches, obesity, 
and cardiovascular disease when compared to controls (Cortese et al. 2013;Fasmer et 
al. 2011a;Fasmer et al. 2011b;Manor et al. 2011;Semeijn et al. 2013a). Whereas 
some have suggested that a less healthy lifestyle (e.g., more risk taking and 
impulsive behavior) may have implications for health status and increased risk for 
mortality (Barkley 2002;Barkley et al. 2008), one of the longest follow-up studies of 
childhood ADHD into adulthood so far (33 years of follow-up) found that in 
particular those with a comorbidity of CD45/APD46 had elevated risk taking behavior 
as adults (Ramos Olazagasti et al. 2013). Significantly increased risk of mortality 
was reported in a prospective follow-up study in younger adults with ADHD 
(Barbaresi et al. 2013). On the other hand, a recent investigation among older adults 
did not find that lifestyle was a mediator of the association between ADHD and 
physical health (Semeijn et al. 2013a). Further studies on the impact of ADHD on 
physical health outcomes are warranted.
45 CD conduct disorder
46 APD antisocial personality disorder
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We found that psychiatric comorbidity and co-occurring disorders had a negative 
impact on the current health condition. In a study on HRQoL47 in younger adults 
with ADHD (69.7 % men; mean age 37.0 years, 67.9 % ADHD, combined type), 
Adler and colleagues (2006) found them to report only slightly above mean scores on 
physical subscales, but significantly below mean scores on mental subscales of the 
Short Form 36® (SF-36) compared to population norms (Adler et al. 2006). An 
association between anxiety/depression and ADHD symptomatology in middle-aged 
and older adults has been reported (Das et al. 2012;Michielsen et al. 2013), and a 
recent investigation found persistent ADHD and co-occurring anxiety/depression to 
mediate poorer quality of life outcome in adulthood (Yang et al. 2013).
Adults with ADHD in our study were significantly less satisfied with life compared 
to age- and gender-matched controls. This has also been reported in other studies 
(Biederman et al. 2006a;Gudjonsson et al. 2009). We found a significant negative 
correlation between ADHD symptom severity and SWLS48 total score. Likewise a 
significant negative association between ADHD symptoms and subjective well-being 
was reported in a sample of middle-aged adults (Das et al. 2012).
Ongoing psychopharmacological treatment for ADHD did not result in statistically 
significant differences in current satisfaction with life when compared to those 
unmedicated. Although available characteristics did not show differences between 
groups in our study, those who were currently taking ADHD medications could have 
been more impaired in other important areas of life, and those symptoms might have 
been ameliorated by their psychopharmacological treatment.
6.1.4 Relationship between time on treatment and outcome 
Taking recent findings on long-term treatment into account (Bejerot et al. 
2010;Wender et al. 2011), we in the SIBBE study drew a line at 24 months of 
treatment or less on one hand and more than 24 months on the other to study the 
impact of time on treatment on outcome.
47 HRQoL health related quality of life
48 SWLS Satisfaction With Life Scale
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We found that those treated for more than 24 months showed significantly more 
favorable outcomes when compared to the group treated for 24 months or less. Our 
results provide some evidence that treatment of adults with ADHD in many cases 
probably should be continued for more than two years.
For patient and doctor it is important to know for how long medication treatment for 
ADHD should be continued after an initial and satisfactory response to 
pharmacotherapy has been established. Studies showed that the amount of clinical 
response over the first six to nine months of treatment with stimulant medication, but 
not after six weeks, predicted adherence to treatment at two years in adults with 
ADHD (Bejerot et al. 2010). Others have found that use of extended-release 
formulations of MPH was associated with longer treatment duration, whereas 
psychiatric comorbidity (e.g., APD and SUD49) was associated with shorter duration 
of stimulant treatments in adults with ADHD (Torgersen et al. 2012).
More information about predictors of non-adherence and placebo response is 
valuable. Variables such as higher educational level, shorter time since ADHD was 
diagnosed, and female sex have been identified as possible predictors of non-
adherence (Kooij et al. 2013). On the other hand have a higher severity of ADHD 
symptoms, younger age, shorter time since ADHD was diagnosed, and lower 
educational level been found to be possible predictors for placebo response 
(Buitelaar et al. 2012). Studies also showed that adults with ADHD often adhere to 
prescribed medication based upon their own opinions, and when it is perceived as 
needed (Brod et al. 2012;Matheson et al. 2013).
Taken the diversity of ADHD patients into consideration (Powell et al. 2011;van de 
Loo-Neus GH et al. 2011) at this point of time, no general conclusions on the 
relationship between time on treatment and outcome for adults with ADHD can be 
drawn. For some adults with ADHD outcome possibly could be a marked 
improvement in ADHD symptoms and social functioning after treatment with MPH 
(Wender et al. 2011). For others outcome probably could be less than a small 
reduction of ADHD symptoms and small functional improvements (Safren et al. 
2005). From a patients’ perspective, access to guidance from experienced clinicians 
49 SUD substance use disorder(s)
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(Matheson et al. 2013), and to meet a person who believe in them and make them 
feel worthwhile and optimistic about their future (Hechtman 1991) seem to be 
important ingredients for treatment adherence and outcome.
6.1.5 Treatment of adult ADHD by primary care physicians (PCPs)
In our study on use and misuse of stimulant medication as reported by patients and 
their PCPs, we found that they agreed on pharmacological, but not the 
nonpharmacological treatments given. PCPs and their patients also agreed on 
patients’ current functioning, and both reported low levels of misuse of stimulant 
medication. Although we did not in particular investigate these topics in the Fifty 
Plus study, it is worth mentioning that in almost 60 % of cases PCPs prescribed the 
drugs for ADHD.
Our results on high levels of PCP-patient agreement about current 
psychopharmacological treatment for ADHD, and current and past prescription of 
stimulant medication are in line with studies that reported high levels of physician-
patient agreements for drug prescription, appointments, and patient referrals to other 
services (Braddock, III et al. 1999;Hooper et al. 2005).
We found low levels of PCP-patient agreement for treatment cessation because of 
side effects and lack of efficacy. Studies have shown that physicians often do not 
explore whether patients have understood and accepted the rationales behind doctors’ 
treatment decisions (Braddock, III et al. 1999). Recently published studies found that 
treatment cessation was often the patient’s own choice, made without informing the 
physician (Matheson et al. 2013;McCarthy et al. 2013). These findings underscore 
the need for better physician-patient relationships, for example in shared-decision 
making (Adams and Drake 2006;Charach and Fernandez 2013). The concept of 
shared-decision making is based on the physicians’ expertise, and the patients’ and 
the physicians’ preferences for treatment, and presuppose that both parties are 
willing to share the information that is needed to build a consensus on preferred 
treatment, and how to implement the latter (Charles et al. 1997). Recent 
investigations into the treatment of children with ADHD found shared-decision 
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making a promising approach, but one that required further study (Brinkman et al. 
2011;Brinkman et al. 2013;Fiks et al. 2011;Moldavsky and Sayal 2013).
The level of PCP-patient agreement for nonpharmacological and psychosocial 
treatment of ADHD in our study was low. Studies have shown that physicians and 
patients often disagree about whether counseling and social support were provided 
during consultations, and unmet patient expectations were reported frequently 
(Hooper et al. 2005;Matheson et al. 2013;Rohrbaugh and Rogers 1994).
We found a much lower frequency of self-reported misuse and diversion of stimulant 
medication than reported previously (Kaye and Darke 2012;Rabiner 2013;Torgersen 
et al. 2013). These results probably can best be explained by the fact that according 
to current guidelines (National Institute for Health and Clinical Excellence 2008;The 
Norwegian Directorate of Health 2007), adults with ADHD should not be transferred 
to PCPs until their condition is stable. This strategy seems even more appropriate as 
a recently published study on trends in office-based treatment of adults with 
stimulant medication in the USA showed a significant increase in stimulant 
prescriptions in cases without a diagnosis of ADHD, and in particular among visits to 
nonpsychiatrists physicians (Olfson et al. 2013). A European study on prescription 
rates of central stimulant medication revealed that a substantial percentage of adults 
with ADHD (30 %) not only were treated with several scheduled drugs at the same 
time, but in addition different physicians prescribed these. The in depth analysis 
showed that these adults more often were prescribed short acting MPH, and with 
substantially higher mean daily dosages than the rest of the sample (The National 
Board of Health and Welfare (Socialstyrelsen) 2012).
We found moderate correlations between patients’ self-reported current functioning 
and their physicians’ clinical judgment of this. Overall, the majority of participants 
did still report significant ADHD symptoms and impaired current functioning. 
Although we concluded that psychopharmacological treatment of adults with ADHD 
can be safely undertaken by PCPs, others have highlighted the advantages of 
treatment by experts when compared to community care (Matheson et al. 2013;Weiss 
et al. 2006). In line with the latter, a recent review of the literature on ADHD and the 
organization of care for individuals with ADHD by the Swedish Council of Health 
Technology recommended that beside of assessment and diagnosis, treatment of 
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ADHD still should be provided by specialized services (Swedish Council on Health 
Technology Assessment 2013).
6.1.6 Psychosocial treatment of adult ADHD
This topic was not investigated extensively in our study. Based on the limited 
information available we found that a substantial number of participants (35-60%) 
had not been provided with any kind of nonpharmacological or psychosocial 
interventions. Thus, our results are well in line with recent findings (Matheson et al. 
2013), and reflect the challenges for many adults with ADHD. Observed differences 
in reported frequencies of perceived nonpharmacological treatment between the two 
study samples were probably related to the fact that almost 24 % of participants in 
the SIBBE study had been diagnosed and treated for the disorder in 
childhood/adolescence. This group may, at least during the time of follow up in child 
and adolescent psychiatric services, have had access to other treatment options than 
pharmacological treatment alone (Matheson et al. 2013).
Our findings were not in line with national (Norwegian Board of Health Supervision 
1998;The Norwegian Directorate of Health 2007), and international guidelines 
(National Institute for Health and Clinical Excellence 2008) that recommend drug 
treatment of ADHD in most cases only as part of a comprehensive and 
multidimensional treatment plan that includes strategies for psychological, 
behavioral, and educational needs. Indeed, the NICE50 guidelines, which recently 
have been found to have superior methodological quality compared with other 
guidelines on ADHD (Seixas et al. 2012), recommend use of pharmacological 
treatment only as first choice in cases with severe impairment (National Institute for 
Health and Clinical Excellence 2008).
Compared to the scientific evidence provided by the large number of both 
randomized and open labeled psychopharmacological treatment studies in adults with 
ADHD, the strength of evidence for nonpharmacological and psychosocial 
interventions still is less convincing (Moriyama et al. 2013;Seixas et al. 
2012;Sonuga-Barke et al. 2013). It has to be taken into account that what today is 
50 NICE National Institute for Health and Clinical Excellence
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recommended as psychosocial treatments for adults with ADHD (e.g., different 
forms of CBT, either individual or group based), hardly were available during the 
time of our investigations. Recent reviews have shown that CBT51 is an effective 
treatment for adults with ADHD (Mongia and Hechtman 2012). Whereas one study 
found the combination of ADHD drug treatment and CBT to be more effective than 
ADHD pharmacotherapy alone (Safren et al. 2005), a recent study did not find that 
ADHD medication significantly augmented the outcome of CBT therapy in adults 
with ADHD when compared to CBT and placebo (Weiss et al. 2012). Therefore, the 
question of the real benefits of combined treatment approaches versus either 
pharmacotherapy or psychotherapy alone is still unresolved and needs further 
investigation.
6.1.7 Variables associated with more favorable outcomes in adults with ADHD 
In line with recommendations by others (Torgersen et al. 2008), we defined more 
favorable outcomes not only by the frequency and severity of ADHD symptoms, but 
also included measurements of current functioning. A more favorable outcome was 
characterized by a combination of an ASRS Screener score below the cutoff of 14, 
and a measurement score on current functioning in line with population norms.
We found that only a limited number of participants (21.5 % in the SIBBE study, and 
19.1% in the Fifty Plus study) fulfilled the predefined criteria for more favorable 
outcomes. Among investigated characteristics unemployment and psychiatric 
comorbidity predicted poorer outcome. With respect to the latter our results were in 
line with findings that have identified psychiatric comorbidity to be an important 
factor for impairment and persistence of ADHD symptoms (Biederman 
2005;Biederman et al. 2010;Biederman et al. 2011;Biederman et al. 2012;Hechtman 
1999;Lara et al. 2009). Likewise has employment been reported to be one of several 
predictors of treatment response in adults with ADHD (Buitelaar et al. 2011a), and 
has in general been found to be important for quality of life (Aronson 1997).
Although employment rates in our study (e.g. 40 % in the Fifty Plus study) were 
somewhat higher than in other Norwegian studies on adults with ADHD (e.g., 22 % 
51 CBT cognitive behavior therapy
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to 24 %), these still were below their population-derived controls (72 to 79 %) 
(Gjervan et al. 2012a;Halmoy et al. 2009;Kupper et al. 2012). The results in our 
study were far beyond the rates of employment (84 %) that recently have been 
presented in a 33-year follow-up study of childhood ADHD (Klein et al. 2012). 
In adults with ADHD occupational underattainments (Biederman et al. 
2008;Rasmussen and Gillberg 2000), lower work performances (De Graaf et al. 
2008) and lower occupational functioning (Barkley et al. 2006) have been reported 
frequently. Severity of ADHD symptoms has been found to be associated with work 
impairment (Safren et al. 2010), and working disability with subsequently disability 
pension (Mordre et al. 2012). In his comprehensive review Barkley concluded that 
no other factor than ADHD per se predicted occupational outcome in adults with 
ADHD (Barkley et al. 2008). This statement has recently been further specified as a 
European study found that in particular symptoms of inattentiveness were a strong 
predictor for occupational outcome in adults with ADHD (Gjervan et al. 
2012a;Gjervan et al. 2013).
We did not find that severity of baseline ADHD symptoms, and ADHD treatment 
before adulthood predicted outcome. These variables have been reported to be 
associated with more favorable outcome in some studies (Biederman et al. 2011; 
Kessler et al. 2005c;Lara et al. 2009;Molina et al. 2009), whereas others found that 
childhood ADHD symptom severity was not predictive for adult outcome (Dalsgaard 
et a. 2002). In a large European study on adults with ADHD stimulant treatment 
during childhood was the strongest predictor for being in work in adulthood (Halmoy 
et al. 2009).
6.1.8 ADHD in middle-aged and late adulthood
Our study on adults aged 50+ with ADHD covers an age range from 50-69 years 
with a mean age of 56 years, and do by this provide a glimmer of light into what 
might happen in middle-aged and late adulthood. On average, participants were 
about 50 years of age when diagnosed with ADHD. By this, our sample was only 
slightly younger than reported in some other studies (Brod et al. 2012;Henry and 
Jones 2011;Manor et al. 2011).
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With an observation time of more than 5 years, our study was one of the first that has 
investigated use, persistence and outcome of psychopharmacological treatment for 
ADHD in this age group. Prior to this, only a few case reports (Biederman 1998;da 
Silva and Louza 2008;Wetzel and Burke 2008), and a pilot study on 11 adults aged 
55 years and older with newly diagnosed ADHD and treated with MPH for at least 
two months (Manor et al. 2011) had been available. Whereas the latter reported 
similar response to MPH treatment as in younger adults, we found that those 
currently treated indeed reported better attention but not hyperactivity/impulsivity 
than participants who were not being treated with ADHD medications. When we 
looked into the ASRS Screener mean scores for our three treatment groups (e.g., 
currently treated, stopped treatment, and treatment naive) all were above the 
recommended diagnostic cutoff of 14 for this instrument, and did not differ 
significantly (for an in depth discussion of this topic see Chapter 6.1.2).
We did not investigate adverse events of psychopharmacological treatment for 
ADHD in particular, but mean dosages of stimulant medications were in line with 
evidence-based recommendations. In the Manor et al. study no significant adverse 
effects of MPH treatment were reported (Manor et al. 2011). A recent review of 
long-term efficacy and safety of treatment with stimulant medication in adult ADHD 
concluded that when cardiac conditions were ruled out at least a modest burden of 
adverse events of treatment with stimulant medication had to be expected (Fredriksen 
et al. 2013). It has recently been pointed out that results from two large registerbased 
studies on ADHD medications and risk of serious cardiovascular events (Cooper et 
al. 2011;Habel et al. 2011), may have been somewhat misleading as a substantial 
number of adults were treated without having a mental disorder diagnosis (Olfson et 
al. 2013). In older adults with ADHD significantly higher rates of heart disease and 
cerebrovascular accidents compared to controls have been reported (Semeijn et al. 
2013a). Thus, increasing cardiovascular problems with age, potentially higher doses 
of therapeutic drugs needed and slower drug elimination are some of the concerns
that have been raised when considering use of stimulant medication in older adults 
(Retz et al. 2011;Weiss et al. 2001;Westover and Halm 2012). Therefore this topic 
still needs further attention.
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Whereas Brod et al. investigated the burden of ADHD in older adults (mean age of 
66 years) compared to younger adults with ADHD (Brod et al. 2012), we were the 
first to study QoL52 in middle-aged and older adults with ADHD compared with 
population norms. In both studies a majority of participants were currently taking 
ADHD medications. The sample of older adults in the Brod study, who on average 
had a higher annual income than the median US household, had a significantly better 
life outlook than their younger counterparts (Brod et al. 2012). Interestingly, an 
investigation in older women with ADHD also reported about some successful lives 
and careers despite having lived with an undiagnosed ADHD for the most of their 
lives (Henry and Jones 2011). In our study the educational level between the index 
and the reference sample did not differ statistically. More adults aged 50+ with 
ADHD were unemployed, and the ADHD sample reported significantly reduced QoL 
when compared with population norms.
Our sample reported small changes in the severity of the core symptoms of the 
disorder compared to ten years ago. In line with this, studies showed that the 
experiences of ADHD symptoms in older adults were not very different from what 
has been reported in younger adults with the disorder (Brod et al. 2012;Henry and 
Jones 2011;Manor et al. 2011;Wetzel and Burke 2008).
We found that ADHD symptom severity, particularly inattention, was significantly 
negatively correlated with daily living and health. Although only a minority of 
participants in the Brod et al. study suspected their ADHD symptoms to be a 
consequence of cognitive problems or dementia (Brod et al. 2012), some studies 
already have looked into possible associations between ADHD and mild cognitive 
impairment (Ivanchak et al. 2012), or different forms of dementia (Golimstok et al. 
2011;Ivanchak et al. 2011) but with inconsistent results.
6.2 Methodological considerations
6.2.1 Study design
Naturalistic follow-up studies in adults with ADHD are warranted to gather more 
information on effectiveness and outcome of treatment over a longer period of time 
52 QoL quality of life
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(Weiss et al. 2006). There are significant challenges to demonstrate long-term effect 
of psychopharmacotherapy due to problem of nonadherence to treatment, self-
selection of treatment continuation, access to treatment, variability in treatment 
quality, and confounding effects of concurrent treatment, co-occurring disorders as 
well as environmental and psychosocial factors (Hazell 2011). According to Hazel it 
is important “to distinguish long-term effects of treatment from effects of long-term 
treatment, as they are not synonymous” (Hazell 2011).
Our investigations on treatment and outcome in adults with ADHD in different age 
groups are descriptive and cross-sectional. They provide a “snapshot” (Hennekens 
and Buring 1987) of experiences of our study groups at one point in time, and can be 
of importance for health authorities in the development of appropriate health care 
strategies for adults with ADHD. The cross-sectional design does not, however, 
permit causal conclusions, and our findings are limited to associations that must be 
interpreted with caution (Kirkwood and Sterne 2011;Thelle 1998). On the other 
hand, hypotheses for future studies can be formulated based on some of these 
findings.
Our study samples were relatively large, and lived geographically spread around the 
country. When financial and other resources are limited, the use of questionnaires 
can be of advantage when one wants to reach as many as possible (Friis and Vaglum 
2002). For example, questionnaires can be answered more flexible than a time-
demanding appointment in the clinic. They can be used in anonymous studies such as 
the Fifty Plus study (Friis and Vaglum 2002). A disadvantage is that we were unable 
to describe those who had decided not to participate in the study. In general, the 
group of non-participants in questionnaire surveys can be challenging as this might 
consist of individuals with either a better or a poorer outcome than reported by 
participants (Friis and Vaglum 2002).
Evidence-based strategies of prenotifaction (Edwards et al. 2007) were used to 
increase response rates in adults with ADHD in the SIBBE study, whereas 
representatives of collaborating partners recommended prenotifaction in the Fifty 
Plus study as unnecessary. Expert and focus groups were used in the development of 
the questionnaires. Whenever appropriate, standardized instruments and items were 
included (Friis and Vaglum 2002). We used reference groups to compare our 
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findings in adults’ aged 50+ with ADHD with population norms. The questionnaire 
for physicians in the SIBBE study contained many identical questions from the 
patient questionnaire, and could by this either confirm or disprove information given 
by participating adults with ADHD.
6.2.2 The sample of the SIBBE study
The eligible sample of the SIBBE study was retrieved from a regional registry that at 
the same time was part of a national registry of adult ADHD. The latter has been 
included in several recently published studies on adults with ADHD with an 
emphasis on for example occupational and functional outcome (Halmoy et al. 2009), 
ADHD and bipolar symptoms (Halmoy et al. 2010), and the impact of cyclothymic 
temperament in adult ADHD (Landaas et al. 2012).
Similar to our investigations, a regional registry on adult ADHD from a different part 
of the country has been the starting point for several other publications on adults with 
ADHD, such as gender differences in untreated adults with ADHD (Rasmussen and 
Levander 2009), clinical characteristics and predictive factors in adults with ADHD 
(Torgersen et al. 2006;Torgersen et al. 2012;Torgersen et al. 2013), functional 
impairment and QoL in adults with ADHD (Gjervan et al. 2012a;Gjervan et al. 
2012b;Gjervan et al. 2013), and the burden of untreated ADHD (Goksoyr and 
Nottestad 2008).
As a majority of research on adult ADHD has been performed in North America, 
studies from other parts of the World, such as Europe are warranted to support, 
correct, fill in, and supply our understanding of the disorder. For instance, a recent 
study showed that European adults with ADHD reported similar baseline 
characteristics when compared with studies from outside of Europe (Upadhyaya et 
al. 2013).
From the eligible sample in the SIBBE study 35 % agreed to participate, which may 
have led to a selection bias. There was no difference on main sample characteristics 
between participants and non-participants (see Chapter 3.3.1 for more information). 
87
Beside that, the response rate in our study was in line with other studies on adult 
ADHD (Gjervan et al. 2012a;Halmoy et al. 2010).
Clinical characteristics in our study, such as age, educational level, rate of 
employment, ADHD subtypes and symptomatology, and psychiatric comorbidity of 
participants, were similiar to what has been reported by others (Gjervan et al. 
2012a;Halmoy et al. 2009;Rasmussen and Levander 2009;Torgersen et al. 
2006;Torgersen et al. 2012). Significantly more men than women had been 
diagnosed with ADHD during childhood and adolescence as in previous reports 
(Halmoy et al. 2009;Torgersen et al. 2012), and mirrors that ADHD in girls until 
recently had attracted little attention (Gaub and Carlson 1997). Overall, it has been 
shown that European adults with ADHD reported somewhat lower numbers of prior 
exposure to stimulant treatment compared with figures from outside of Europe 
(Upadhyaya et al. 2013).
The SIBBE study sample comprised unlike other studies a quite balanced gender 
distribution, which may have influenced the findings. As documented by others, 
studies of gender differences as to severity of symptoms and clinical presentations 
are limited in adults with ADHD (Biederman et al. 2004;Rasmussen and Levander 
2009). Although we found the study sample to be fairly representative, we have to 
acknowledge that those with less benefits of treatment may have chosen not to 
participate, which may have biased our findings (Surman et al. 2013).
6.2.3 Primary care physicians (PCPs)
According to national guidelines, PCPs can become responsible for 
psychopharmacological treatment of adults with ADHD after a specialist has 
diagnosed the disorder, initiated psychopharmacological treatment and considered 
the condition as stable (The Norwegian Directorate of Health 2007). In line with this, 
recent investigations showed that psychopharmacological treatment of ADHD by 
PCPs has increased substantially (Asheim et al. 2007;Lillemoen et al. 2012). In 2008 
nearly 80 % of a national sample of PCPs was found to prescribe stimulant 
medication due to the diagnosis of ADHD (Lillemoen et al. 2012). International 
guidelines on ADHD (National Institute for Health and Clinical Excellence 2008), 
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and a recent Scandinavian chart review study (Pottegard et al. 2012) highlighted that 
general practitioners are an essential part of long-term treatment in patients with 
ADHD.
Among included participants in the SIBBE study (n=368), a majority of 274 adults 
with ADHD (74.5 %) reported treatment for their disorder by a PCP (Paper II). In 
our study on use and misuse of stimulant medication as reported by patients and their 
PCPs, more than 40 % of the eligible sample could not be included in the analysis 
because of a lack of response by the PCPs responsible for their ADHD treatment. We 
were unable to control for potential differences between PCPs who had participated 
and those who did not. Among participating PCPs most reported on one adult with 
ADHD (93.7 %), whereas nine reported on two patients, and one reported on three. 
Female PCPs treated 31 % of the participants. 
In the questionnaire for PCPs we did not address the patients’ adherence, time on 
treatment, number of treatment cessations, or who that had made the decision to stop 
pharmacotherapy for ADHD in particular. Neither did we investigate the duration of 
the physician-patient relationship, and the frequency of appointments for treatment of 
ADHD. This may have limited our conclusions.
6.2.4 The sample of the Fifty Plus study
Participants in this study were recruited from the national patient organization, which 
is not necessarily a representative sample of all adults with ADHD. As membership 
of a patient organization may require personal engagement and continuity, more 
severely impaired adults with ADHD may have been underrepresented, which could 
limit the generalizability of our findings in the Fifty Plus study. About one-third of
the eligible participants did not participate, and it is possible that this group may have 
comprised adults with more severe ADHD.
Although baseline information was limited, research showed that the levels of 
functional and psychosocial impairments in undiagnosed adults with ADHD are 
quite similar to those in adults who have been diagnosed with ADHD (Able et al. 
2007;Biederman et al. 2006a;Shekim et al. 1990). Our study sample consisted of 
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more women than men. Findings by others have indicated that gender differences in 
the severity of symptoms and clinical presentations are limited in adults with ADHD 
(Biederman et al. 2004;Rasmussen and Levander 2009).
The frequency of self-reported medical problems in the Fifty Plus sample was higher 
than reported in samples of younger adults with ADHD (Barkley et al. 2008). 
Conversely, and in line with our findings, higher numbers of medical disorders than 
expected were found in a study of older adults diagnosed with ADHD (Manor et al. 
2011). The possibility of an increased risk of physical health problems in ADHD, for 
example due to impulsive behavior, poor decision making or executive function 
deficits have been highlighted recently (Nigg 2012).
6.2.5 Reported measurements
The diagnostic assessment process of adult ADHD as a clinical diagnosis was in line 
with national recommendations and guidelines (Norwegian Board of Health 
Supervision 1998;The Norwegian Directorate of Health 2007), clinical 
recommendations  (McCann and Roy-Byrne 2004;McGough and Barkley 
2004;Murphy and Adler 2004;Weiss and Murray 2003), and a recently published 
European consensus statement on adult ADHD (Kooij et al. 2010). The diagnosis of 
ADHD in adults was made according the diagnostic criteria in ICD-10 and DSM-IV, 
respectively. Although recommended by some, no adjustments with respect to time 
of onset or number of criteria needed for the diagnosis of adult ADHD were made 
(Barkley et al. 2008;Kooij et al. 2005;Kooij et al. 2010). Interestingly, a recent 
investigation found that age and gender had minimal effect on ADHD symptoms 
(Gomez 2013). Findings from the latter study also suggested that a hyperkinetic 
disorder model, with the three core symptoms as separate factors might fit the 
assessment of adults better than the DSM-IV approach with inattention and 
hyperactivity/impulsivity as two separate factors (Gomez 2013).
Results from our study are mainly based on self-reports, and the reliability can be 
questioned. Several studies have documented that adults with ADHD are reliable 
reporters of their current symptoms (Dias et al. 2008;Kooij et al. 2008;Magnusson et 
al. 2006;Murphy and Schachar 2000), and even are at risk to underestimate their own 
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ADHD related impairment (Adler et al. 2008;Barkley et al. 2002;Manor et al. 
2012;Sibley et al. 2012).
The ASRS v1.1 Screener (Kessler et al. 2005a) is a widely used instrument to assess 
ADHD symptoms in adults, and has been translated into several languages and 
validated for different clinical populations (Daigre et al. 2009;Kim et al. 2013;Morin 
et al. 2013;Obel et al. 2009;Rodriguez et al. 2007;van de Glind et al. 2013). The 
instrument has been found to have good test-retest reliability (Matza et al. 2011), and 
an adequate sensitivity and specificity in specialized services and primary care 
(Dakwar et al. 2012;Hines et al. 2012). A two-factor solution with inattentiveness 
and hyperactivity/impulsivity as separate factors have been proposed (Hesse 2013), 
and has been applied in a large population based study in middle-aged adults recently 
(Das et al. 2012). Although the ASRS Screener has a strong concordance with 
clinical diagnoses, the instrument has some weaknesses with respect to other medical 
conditions and comorbidities, and does not assess for inconsistencies or malingering 
(Hines et al. 2012). Compared with other adult ADHD rating scales, the ASRS 
Screener has been found to be the simplest and shortest instrument to administer, and 
has been widely accepted in clinical practice and research (Dakwar et al. 2012;Rosler 
et al. 2010b).
The SCL-90-R (Degoratis 1994) has been used in several studies in adult ADHD to 
assess co-existing psychopathology (Gjervan et al. 2012a;Hesslinger et al. 
2002;Murphy et al. 2002;Rosler et al. 2010a;Shekim et al. 1990). These studies 
reported elevated rates of psychological distress on all subscales of the SCL-90-R
when compared to controls and population norms. Findings from the Norwegian 
expert teams correspond well with the latter (Aanonsen et al. 2005). Nine selected 
items of the SCL-90-R with an acceptable sensitivity (75%) but only moderate 
specificity (54%) have been proposed as a new useful rating scale for ADHD 
recently (Eich et al. 2012). The SCL-90-R has also been applied to investigate the 
psychopathology in parents of children with ADHD. Among these parents with 
lifelong persistent ADHD higher scores of psychopathology measured with the SCL-
90-R than controls and parents with remitted ADHD was reported (Steinhausen et al. 
2013). These findings correspond well with initial reports on parents of hyperactive 
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children some decades ago, where increased rates of psychiatric comorbidity were 
found (Cantwell 1972;Morrison and Stewart 1971;Morrison and Stewart 1973).
The MHI-5 (Ware, Jr. et al. 2000) has to the best of our knowledge not been applied 
solely in studies on adult ADHD. The instrument is a subscale of the Short From 
(SF-36), which has been used in several investigations on adult ADHD (Adler et al. 
2006;Gjervan et al. 2012b;Matza et al. 2007). In some of these studies baseline MHI-
5 levels below population norms have been reported. Improvement after 
psychopharmacological treatment for the disorder has been described (Adler et al. 
2006). Others have found symptoms of hyperactivity/impulsivity to predict mental 
health outcomes (Gjervan et al. 2012b). The MHI-5 correlates highly with several 
short forms of the SCL, and one operational advantage of this instrument over the 
SCL is that is has been used in surveys on mental and on general health (Strand et al. 
2003).
The SDS (Leon et al. 1997) has been frequently used as a secondary QoL outcome 
measure in psychopharmacological studies in groups of younger adults with ADHD 
(Adler et al. 2006;Buitelaar et al. 2011b;Fallu et al. 2006;Michelson et al. 
2003;Rosler et al. 2013;Spencer et al. 2006;Weiss et al. 2012). In some of these 
studies significantly improved SDS scores after a longer period of treatment were 
reported (Adler et al. 2006;Buitelaar et al. 2011b), whereas others discussed whether 
a short-term improvement on SDS scores could decrease over time (Rosler et al. 
2013). Besides this, the latter study found that improvement on SDS scores was fully 
mediated by improvements on an investigator rated ADHD scale (Rosler et al. 2013). 
Thereagainst others reported that changes in SDS scores were predicted by patients’ 
characteristics such as age, sex, and comorbid depression (Spencer et al. 2006).
The EQ-5D (The EuroQol Group 1990) has not been used extensively as a 
measurement of QoL in the field of ADHD. This brief QoL instrument was used to 
assess HRQoL in children with ADHD (Matza et al. 2005b), and has recently been 
listed as one of the instruments in a comparison study on European and non-
European adult ADHD (Upadhyaya et al. 2013). Although it has been argued that the 
use of a generic measure of HRQoL may not capture serious impairments unique for 
the disorder (Brod et al. 2005;Weiss et al. 2010), our aim in the Fifty Plus study was 
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to enable a comparison with population norms to investigate the impact of ADHD in 
middle-aged and late adulthood.
The SWLS (Diener et al. 1985) has not been used frequently in ADHD research so 
far. We are aware of only one study where this instrument was used to assess 
satisfaction with life among university students (Gudjonsson et al. 2009). Here, an 
association between ADHD symptoms, comorbid difficulties, and reduced SWLS 
scores was found (Gudjonsson et al. 2009).
6.2.6 Strengths of the study
Our results are strengthened by the relatively large and fairly representative samples 
of adults with ADHD in different age groups. The naturalistic design and length of 
observation time in the SIBBE study reflects common clinical challenges with respect 
to follow up of adults with ADHD. Information from multiple sources (e.g., self-
reports, physician reports, rating scales) has contributed to investigate use, 
persistence and outcome of mainly psychopharmacological treatment in adults with 
ADHD. Validated instruments were used to enable comparison with population 
norms. In the Fifty Plus study information was collected anonymously, which may 
have contributed to honest answers from participants. The study consists of both 
clinical and non-clinical samples of adults with ADHD.
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7. CONCLUSIONS
This study has investigated treatment and outcome in adults with ADHD in different 
age groups. Taking methodological considerations and study limitations into 
consideration, the following conclusions arise:
 Among participants in different age groups a majority reported current 
psychopharmacological treatment for ADHD mainly with stimulant 
medication, 4-5 years after initiation.
 Those currently being treated psychopharmacologically for ADHD reported 
significantly less ADHD core symptoms than those currently not medicated 
for the disorder. However, current mental and psychosocial functioning was 
not significantly different between treatment groups, and considerably 
impaired relative to controls and clinical cutoff criteria.
 Psychopharmacological treatment for ADHD for more than two years was 
associated with better functioning than treatment for two years or less.
 Primary care physicians and their ADHD patients agreed on the 
pharmacological, but not the nonpharmacological treatments given. 
Physicians and patients reported low levels of misuse of stimulant 
medication. The results suggest that primary care physicians can safely 
undertake psychopharmacological treatment of ADHD when the condition is 
stable.
 Use of psychosocial treatment programs for ADHD, as part of a 
comprehensive treatment plan and in addition to psychopharmacological 
treatment for the disorder, was limited.
 Quality of life in adults with ADHD was significantly reduced compared with 
population norms.
 Comorbidity, unemployment, and ADHD symptom severity were associated 
with less favorable outcomes.
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 The negative impact of ADHD persisted into middle aged and late adulthood.
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8. IMPLICATIONS
8.1 Clinical implications
The result with respect to maintainment or long-term persistence of pharmacotherapy 
is an important clinical finding as it challenges the common understanding that this 
group of patients often terminate treatment at an early stage.
Our findings suggest that long-term treatment with stimulant medications is 
experienced as beneficial for adults with ADHD. Therefore efforts should be made 
so that adults with ADHD are given the option of long-term pharmacological 
treatment for the disorder. It is our opinion that several actions can be taken to 
improve maintainment of pharmacotherapy and possibly the long-term outcome of 
the disorder.
For example, a lesson can be learned from a study where only those adults with 
ADHD who had experienced a robust investigator rated symptom reduction of at 
least 50 % after initial pharmacotherapy, were included in a longer lasting open label 
trial of treatment with MPH53. These adults reported high rates of symptom reduction 
and clinical improvement over time (Wender et al. 2011). Compared to nowadays-
clinical practice this would mean that pharmacological treatment of each adult with 
ADHD should follow a predefined set of criteria and time span for evaluation with 
respect to e.g., treatment continuation or switching to a different compound when the 
expected symptom reduction not has been achieved. In line with the aforementioned, 
a recent review on head to head comparison studies of long-acting MPH 
formulations concluded: “Different patients have both different treatment needs and 
responses to MPH. There is now clear evidence that, in order to optimize the 
treatment of ADHD symptoms, a tailored approach to treatment is required. This 
involves both an initial titration onto medication and a continued follow up, with 
careful adjustments in dose and often in MPH formulation. It is important to track 
symptoms and response across the day” (Coghill et al. 2013).
A minority of participants in our study had stopped treatment with medication for 
ADHD, either due to side effects, lack of efficacy, or other reasons. Already years 
53 MPH methylphenidate
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ago Weiss and Hechtman wrote: “While stimulants were viewed as more beneficial 
than other medications, taking any “pills” was strongly disliked by the majority of 
hyperactive adults. … Reasons for disliking medication seemed relatively unrelated 
to its efficacy, but were sometimes related to its side effects. Subjects felt that the 
physicians who prescribed their medication had not adequately discussed why this 
was indicated and what the possible side effects might be.” (Weiss and Hechtman 
1993). It is our opinion that a more mutual understanding of commitment and 
adherence to treatment can contribute substantially to better outcome in adults with 
ADHD (see for example the concept of “dynamic adherence” suggested by Gearing 
et al. 2011). Research on pharmacological treatment of ADHD has shown that 
“patients want to feel supported in their decision to stop, to understand possible 
outcomes, and to be able to reaccess medication if it is needed” (Wong et al. 2009). 
In a mutual relationship, this would assume an “ethical responsibility” from both 
parts, e.g., the physician and the patient (Rothenberger and Rothenberger 2013).
Our study provides some evidence that treatment of adults with ADHD in many 
cases should be continued for more than two years. This has important clinical 
implications for physicians and patients when to discuss expected length of and 
commitment to treatment after a diagnosis of ADHD has been established. 
Psychopharmacological treatment was associated with reduced ADHD symptom 
severity when compared to those who were not currently medicated for the disorder. 
For the majority of participants ADHD symptom severity and current functioning 
still was above remission as a goal of treatment. It is our opinion that it is necessary 
to tailor individual treatment schedules (Coghill et al. 2013;Powell et al. 2011), 
where treatment is offered in a systematic way with regular visits and a continuous 
approach to optimize adherence and outcome by providing available treatment 
strategies (Lundh et al. 2013;van de Loo-Neus GH et al. 2011). As the majority of 
participants in our study were treated with stimulant medications, one should be 
cautious to generalize the findings to treatment with nonstimulant medications.
We found that pharmacological treatment of adult ADHD safely can be transferred to 
PCPs54 when the condition is stable. This is of clinical importance as PCPs are an 
essential part of the treatment system. The public opinion of pharmacotherapy of 
54 PCP primary care physician
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adult ADHD is often challenged by a suspected risk of misuse and diversion of 
stimulant medication. Therefore, the low rates of reported misuse of stimulant 
medication, and the high level of PCP-patient agreement on this topic are of clinical 
relevance for adults with ADHD, their physicians, and National Health Authorities.
In our study adults with ADHD rarely were provided psychosocial treatment 
programs either as part of a comprehensive treatment plan or alone. This is of clinical 
importance as guidelines on ADHD highlights the need for multidimensional and 
comprehensive interventions. Taken the results of a limited reduction in ADHD 
symptomatology and impaired current functioning in a majority of cases in our study 
into consideration, the need for increased availability of such interventions is 
obvious. Simultaneously it is important to choose evidence-based treatment 
approaches rather than programs with less scientific evidence. Studies have shown 
that structured CBT55 programs are superior to supportive therapy, discussion 
groups, and patient education (Knouse and Safren 2010;Philipsen 2012). The lack of 
long-term benefits of patient education also has been reported from other disciplines 
in medicine (Duke et al. 2009;Riemsma et al. 2003). We strongly recommend that 
educational programs for professionals should rely on these findings.
There is a need for an improved physician-patient relationship. Several studies have 
shown that structured educational programs can improve the quality of services 
provided by PCPs for patients with ADHD (Carroll et al. 2013;Epstein et al. 
2008;Fallu and Klassen 2013;Wolraich et al. 2010). Efforts should be made to extend 
these programs to cover all aspects of adult ADHD.
We were able to show that a majority of middle-aged and older adults with ADHD 
reported to be currently on pharmacological treatment for the disorder. As still little 
is known about pharmacological treatment of ADHD in these age groups, physicians 
have to be particularly aware of an increased risk of side effects, and the possibility 
of a different pharmacotherapeutical profile. It is our opinion that it is important to 
update guidelines on ADHD with respect to these age groups. This seems even more 
necessary as for example memory clinics in an increasing manner will have to deal 
with assessment of ADHD (Fischer et al. 2012;Pose et al. 2013), and probably will 
55 CBT cognitive behavior therapy
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be challenged by the lack of a good screening instrument for ADHD in late 
adulthood (Semeijn et al. 2013b).
Middle-aged and older adults with ADHD reported significantly reduced QoL56
when compared to controls. We observed increased rates of unemployment in our 
index group compared to normal controls. In addition, relational problems, and the 
burden of ADHD as a disorder that “runs in families” have to be taken into 
consideration. Many of our participants had children, and even grandchildren who 
also had been diagnosed with ADHD. Therefore, psychosocial intervention programs 
addressing the multiple challenges of e.g., living with the disorder and taking care of 
the family have to be developed and addressed in particular. An increased 
collaboration with patient organizations can be valuable. 
Prolonged treatment by specialists should be considered when ADHD symptom 
scores are high and dysfunctions significant despite adequate treatment options. This 
will require comprehensive services that may be difficult to establish in all areas. 
Therefore some have argued for specialized lifetime ADHD clinics, a topic that has 
to be discussed further.
8.2 Considerations for future research
The results presented in this thesis are mainly based on self-reports of selected 
samples of adults with ADHD in different age groups.
We presented in Paper I and Paper III that those currently treated 
psychopharmacologically reported less severe ADHD symptomatology than those 
not medicated, but the majority of patients was not in remission. Independent of 
treatment status a large majority of participants reported impaired current 
functioning. Use, persistence and outcome of long-term psychopharmacological 
treatment of adults with ADHD in clinical settings should be investigated further in 
prospective, longitudinal follow-up studies. The advantage of multiple sources of 
information (e.g., patient report, clinician report, objective measures, register data, 
56 QoL quality of life
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regular evaluation), and a structured assessment of nonpharmacological interventions 
should be utilized.
In Paper I we presented some evidence that treatment of adults with ADHD for 
more than two years was associated with better functioning than treatment for two 
years or less. Our assumptions were based on previous research of long-term 
treatment. The appropriateness of such a premise should be investigated further.
Primary care physicians (PCPs) have become an essential part in treatment of adults 
with ADHD. Although we as presented in Paper II found that PCPs and their 
ADHD patients agreed on pharmacological treatments given, we did not investigate 
several important aspects, for example treatment satisfaction, persistence of 
treatment as reported by PCPs, and whether provided psychopharmacological 
treatment was in line with recommendations in particular. The usefulness of outlined 
strategies for improved treatment adherence in adults with ADHD such as shared 
decision making, and the concept of dynamic adherence should be investigated in 
future research studies.
The frequency of multidimensional treatment approaches including 
nonpharmacological/psychosocial interventions in our studies was low as reported in 
Paper I, Paper II, and Paper III. There is, on the other hand, an increasing 
awareness and scientific evidence for the effectiveness of either individualized or 
group oriented psychotherapeutical interventions in adults with ADHD. As this kind 
of structured treatment programs so far rarely are available in clinical practice, other 
types of psychosocial interventions such as patient education are provided, and they 
lack sufficient scientific evidence. Future research should investigate the 
effectiveness of patient education versus structured treatment programs. 
Recommendations for best possible treatment approaches for adults with ADHD 
could be supported by results from nonpharmacological head to head studies.
Our findings of significantly impaired quality of life in middle-aged and older adults 
with ADHD compared to controls, and high rates of use and persistence of 
psychopharmacological treatment as presented in Paper IV and Paper III
respectively, are preliminary, and should therefore be investigated further in 
prospective studies of clinical samples.
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APPENDIX I
Etterundersøkelse blant voksne med ADHD Studie om iverksatt 
behandling, behandlingsforløp og effektvurdering (SIBBE) - spørreskjema 
for pasient
9. Om du samtykker vil vi gjerne sende et spørreskjema til din lege. 
Vennligst oppgi legens navn og adresse her:     
Navn: __________________________________________________________________________________
Legekontor:_____________________________________________________________________________
Gate:___________________________________________________________________________________
Postnummer og -sted: ___________________________________________________________________
10. Hvis det er noe mer du gjerne vil fortelle, setter vi stor pris på om du noterer det her eller 
skriver det ned på et eget ark.
SAMTYKKE - PROSJEKTDELTAKER 
for studien “Etterundersøkelse blant voksne med ADHD – Studie om iverksatt behandling, 
behandlingsforløpog effektvurdering” (SIBBE)
Deltakelse i studien er basert på ditt frivillige, informerte samtykke. Dersom du ønsker mer informasjon kan
du ta kontakt med oss. Dersom du sier ja til å delta i studien, må du signere under.
Jeg, __________________________________________________________________  (navn med blokkbokstaver),
bekrefter at jeg har mottatt skriftlig informasjon om studien, har fått anledning til å innhente den informasjon
jeg har hatt behov for, og er villig til å delta i prosjektet. 
Dato:___________________________     Signatur: ____________________________________________________
Send utfylt  spørreskjema tilbake til oss i vedlagte ferdig frankerte svarkonvolutt.
Tusen takk for hjelpen.  
ADHDlivet
ID-nummer: 
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5Spørreskjema for pasient:
Etterundersøkelse blant voksne med ADHD
Studie om iverksatt behandling, behandlingsforløp og effektvurdering (SIBBE)
Ullevål universitetssykehus HF
v/prosjektleder Michael B. Lensing
Bygg 29, 0407 Oslo  
Tlf.: 22 11 75 78 • Mobil: 41 46 99 86
mien@uus.no • www.ulleval.no/adhd-livet
ADHDlivet
ID-nummer: 
ADHDlivet
ADHDlivet
Oslo, januar 2009
Før jul fikk du tilsendt et spørreskjema om voksne med ADHD som i perioden 1997-2005 fikk 
tilrådet behandling med sentralstimulerende legemidler av Sakkyndig Team for hyperkinetisk 
forstyrrelse/ADHD i helseregionene Sør & Øst. Du hadde kanskje ikke tid til å svare på det da og
jeg tillater meg derfor å sende spørreskjemaet en gang til. 
Hvordan svare på spørreskjemaet?
Du kan enten besvare selve spørreskjemaet og sende det tilbake til oss, eller du kan benytte deg
av en elektronisk besvarelse via Internett. Foretrekker du dette, må du bruke følgende 
fremgangmåte: 
1. Gå til vår hjemmeside www.ullevål.no/adhd-livet 
2. Velg pasientskjema. Du vil da bli viderekoblet til en ekstern, sikker side 
3. Logg deg inn med ditt ID-nummer (du finner det øverst til høyre på neste side)
4. Svar på spørsmålene 
5. Det elektroniske spørreskjemaet har ikke fritekst. Hvis du ønsker å kommentere noe må du 
derfor skrive dette ned og sende til oss. Du må gjerne benytte vedlagte svarkonvolutt til dette  
Hvis du synes det er vanskelig å svare på spørsmålene, kan du be noen du har tillit til om hjelp.
Du kan også gjerne ta kontakt med meg på telefon 221 175 78 (arbeid), 414 699 86 (mobil) eller
sende meg en E-post på mien@uus.no. 
Det er lagt ved et Flax-lodd som takk for din velvilje. 
Oppdatert informasjon om studien finner du på vår hjemmeside www.ulleval.no/adhd-livet 
Michael B. Lensing
Prosjektleder
ADHDlivet
A.    Behandling
1. Har du fått medikamentell behandling mot ADHD? Ja Nei       
(Hvis nei, gå til spørsmål 9)
2. Bruker du fortsatt et medikament mot ADHD? Ja Nei       
(Hvis nei, gå til spørsmål 6)
3.  Hvilket medikament mot ADHD bruker du nå? (Sett bare ett kryss)
Ritalin Ritalin kapsler Concerta Dexedrine Strattera
Annet hva: 
4.  Hvor mange kapsler/tabletter bruker du pr. dag? .............................   
5.  Hvor ofte har du i løpet av den siste uken utelatt (glemt) å ta din ADHD medisin? 
(Bare ett kryss, fortsett deretter til spørsmål 9)
Aldri
1-2 ganger
3-5 ganger
6-10 ganger
mer enn 10 ganger
6.   Omtrent hvor lenge brukte du medikamentell behandling mot ADHD? ............... (angi tidsperiode)
7.  Hvorfor ble den medikamentelle behandlingen avsluttet?  (Kryss av for det som passer)   
Bivirkninger Manglende/lite tilfredsstillende effekt             Misbruk               Bedring
Graviditet Manglende oppmøte Vet ikke
Annet            hva: 
8.  Hvilket medikament mot ADHD var det siste du brukte? (Bare ett kryss)
Ritalin Ritalin kapsler Concerta Dexedrine                 Strattera
Annet           hva: 
9.   Har du fått annen behandling mot ADHD? (Kryss av for det som passer) 
Psykoterapi/Samtalebehandling/Livsstilveiledning
Gruppeterapi
Kosthold/Ernæring
Vold-/Sinnemestring
Annet, hva 
Ikke aktuelt
ID-nummer: 
Veldig dårlig   Dårlig Middels God Veldig god
0   1         2         3        4          5         6 7        8        9 10
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10.  Er det i tillegg iverksatt andre tiltak?  (Kryss av for det som passer)
Ansvarsgruppe
Individuell plan
Sykepenger/sykelønn/rehabiliteringspenger
Yrkesrettet attføring
Uførepensjon, tidsbegrenset uførepensjon
Arbeidsledighetstrygd
Andre ytelser, hva
Ikke aktuelt
11.  Har du noen gang brukt høyere doser ADHD medisin enn foreskrevet av legen?   Ja         Nei  
12.  Har du noen gang brukt ADHD medisin sammen med narkotia?                           Ja         Nei  
13.   Har du noen gang solgt din ADHD medisin? Ja         Nei
14.  Har du opplevd bedring i forbindelse med behandling mot din ADHD? 
(Sett ring rundt aktuelt tall)
15. Hvordan vil du samlet sett vurdere kvaliteten på behandlingen du har fått?
(Sett ring rundt aktuelt tall)
16. Hvis det er noe du ønsker å fortelle om behandlingen/tiltakene mot ADHD, setter vi stor pris på
om du noterer det her eller skriver det ned på et eget ark.
Ingen   Lite Moderat Mye Veldig mye
0   1         2         3        4          5         6 7        8        9 10
 A D H D livet
ID-nummer: 
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B.    Hvordan har du det?
De neste spørsmålene handler om hvordan du føler deg og hvordan du har det. Kryss av for det
svaltermativet som best beskriver dette. 
1. Har du noen gang i voksen alder hatt en periode hvor du følte deg full av energi, hadde økt
tiltaktslyst, lite søvnbehov, tankene raste av gårde, at du snakket uvanlig mye eller satte i gang
mange prosjekter?     Ja               Nei
2. Har du hatt noen periode i livet der du har vært vedvarende irritert slik at du skrek til folk,
startet krangler eller begynte å slåss med noen utenom familien?      Ja               Nei
3. Hvor ofte har du i løpet av den siste uken
a. Følt deg veldig nervøs?
b. Vært så langt nede at ingenting har kunnet muntre deg opp?
c. Følt deg rolig og harmonisk?
d. Følt deg nedfor og trist?
e. Følt deg glad?
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4. Kryss av for det alternativet som best beskriver hvordan du har
følt og oppført deg den siste uken.
a. Hvor ofte har du problemer med å avslutte en oppgave etter at de 
interessante delene er unnagjort?
b. Hvor ofte er det vanskelig for deg å få orden på ting når du skal utføre 
en oppgave som krever organisering?
c. Hvor ofte har du problemer med å huske avtaler eller forpliktelser? 
d. Når du har en oppgave som krever at du tenker nøye igjennom det du skal 
gjøre, hvor ofte unngår eller utsetter du å begynne på den?
e. Hvor ofte sitter du og fikler med noe når du må sitte lenge i ro?
f. Hvor ofte føler du deg overdrevet aktiv og tvunget til å gjøre noe, som 
om du var drevet av en indre motor?
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ID-nummer: 
Dårlig   Mindre god God Meget god Utmerket
0   1         2         3         4        5         6 7        8        9 10
Ikke i det hele tatt   Lite Moderat Markert Veldig mye Ikke aktuelt
0   1         2         3      4        5         6 7        8        9 10
Ikke i det hele tatt   Lite Moderat Markert Veldig mye Ikke aktuelt
0   1         2         3      4        5         6 7        8        9 10
Svært
misfornøyd
Temmelig 
misfornøyd         
På det 
jevne
Temmelig 
fornøyd
Svært 
fornøyd
 A D H D livet
5. I hvilken grad har følelsesmessige problemer forstyrret ditt arbeid den siste uken?
(Sett ett kryss)
6. I hvilken grad har følelsesmessige problemer forstyrret ditt sosiale liv den siste uken?
(Sett ett kryss)
7. I hvilken grad har følelsesmessige problemer forstyrret ditt familieliv/ditt ansvar for hjemmet
den siste uken?   (Sett ett kryss)
8. I det store og hele, vil du si at helsen din er:   (Sett ett kryss)
9. Alt i alt, hvor fornøyd er du med livet ditt?:  (Sett ett kryss)
Ikke i det hele tatt   Lite Moderat Markert Veldig mye Ikke aktuelt
0   1         2         3      4        5         6 7        8        9 10
ID-nummer: 
C. Litt om deg
1. Hvilken sivilstand har du?
Gift Skilt/separert Samboer Enkemann/-kvinne Enslig Annet
2. Er du i inntektsgivende arbeid?     Ja, full tid            Ja, deltid               Nei       
3. Hvilken utdannelse har du fullført? 
Ingen
9-årig grunnskole
1-2 årig videregående
Videregående yrkesfaglig
3-årig videregående, allmennfaglig, gymnas
Høyskole
Universitet
Annet
4 Får du eller har du fått behandling for noen av de følgende sykdommer eller helseproblem?
(Kryss av for det som passer)
Allergi
Angst
Astma
Depresjon
Epilepsi
Hjerte/kar sykdom
Migrene
Spiseforstyrrelse
Stoffskiftesykdom
Søvnvansker
Tourettes syndrom/Tics
Andre langvarige sykdommer eller helseproblemer
Hvis “andre langvarige...” beskriv hva:
Ikke aktuelt 
5. Tror du at du har en alvorlig uoppdaget sykdom?    Ja             Nei       
6. Har du fått behandling for rusmiddelmisbruk?         Ja             Nei
7. Er skjemaet besvart av deg?                                    Ja             Nei       (Hvis nei, gå til spørsmål 8)
8. Om nei, er skjemaet besvart av:
Ektefelle/samboer          Pårørende          Tjenesteyter          Annet          beskriv: __________________
 A D H D livet
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APPENDIX II
Etterundersøkelse blant voksne med ADHD Studie om iverksatt 
behandling, behandlingsforløp og effektvurdering (SIBBE) - spørreskjema 
for lege
Navn på medikament
12 Har det vært mistanke om at pasienten noen gang har 
brukt høyere doser ADHD medikasjon enn forskrevet?           Ja               Nei         Vet ikke
13 Har det vært mistanke om at medikamentet mot ADHD 
har blitt brukt sammen med narkotika?                      Ja               Nei        Vet ikke
14 Har det vært mistanke om at pasienten har solgt 
sin ADHD medisin?                      Ja               Nei        Vet ikke
15 Er det gitt annen behandling mot ADHD? (Kryss av for det som passer)
Psykoterapi/Samtalebehandling/Livsstilveiledning
Gruppeterapi
Kosthold/Ernæring
Vold-/Sinnemestring
Annet, beskriv 
Ikke aktuelt
16 Er det iverksatt andre tiltak? (Kryss av for det som passer) 
Ansvarsgruppe 
Individuell plan 
Sykepenger/sykelønn/rehabiliteringspenger
Yrkesrettet attføring 
Uførepensjon, tidsbegrenset uførepensjon 
Arbeidsledighetstrygd 
Andre ytelser, beskriv
Ikke aktuelt       
17 Er det gitt behandling for rusmiddelmisbruk? Ja        Nei
18 Er det gitt samtidig annen medikamentell behandling?    Ja        (angir hva) Nei
19 Ut fra din kliniske erfaring, hvordan vil du vurdere pasientens nåværende fungering? 
(Bare ett kryss)
20 Om det er noe du ønsker å kommentere vil vi sette stor pris på om du vil notere det her 
eller på et eget ark
Kryss av for ditt bokønske, så får du tilsendt boken pr. post i løpet av kort tid.
Hoem S (2008) ADHD - en håndbok for voksne med ADHD. 2. utgave
Ryffel-Rawak D (2007) Kvinner med ADHD
Rønhovde, LI (2008) Ti tanker i huet og ingen på papiret
Youmans M (2008) Helt hyper?
Zeiner P (red) (2004) Barn og unge med ADHD 
Legg skjemaet i den frankerte og forhåndsadresserte returkonvolutten og send det til oss. 
Tusen takk for hjelpen.
Alvorlig nedsatt Noe nedsatt På det jevne God Svært god
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Spørreskjema for lege
Etterundersøkelse blant voksne med ADHD
Studie om iverksatt behandling, behandlingsforløp og effektvurdering (SIBBE)
ADHDlivet
ADHDlivet
Ullevål universitetssykehus HF
v/prosjektleder Michael B. Lensing
Bygg 29, 0407 Oslo  
Tlf.: 22 11 75 78 • Mobil: 41 46 99 86
mien@uus.no • www.ulleval.no/adhd-livet
21 Har pasienten fått medikamentell behandling mot ADHD?                              Ja                Nei       
(Hvis nei, gå til spørsmål 15)
2 Bruker pasienten fortsatt et medikament mot ADHD?      Ja                Nei                    
(Hvis nei, gå til spørsmål 5) 
3 Hvilket medikament benytter pasienten nå? (Bare ett kryss)
Ritalin Ritalin kapsler Concerta Dexedrine            Strattera
Annet           hva: 
Oslo, februar 2009
Kjære  
Ad:  
Du fikk for en stund siden tilsendt et spørreskjema om ovennevnte pasient som har ADHD og som i
perioden 1997-2005 fikk tilrådet behandling med sentralstimulerende legemidler av Sakkyndig Team
for hyperkinetisk forstyrrelse/ADHD i helseregionene Sør & Øst. Pasienten har samtykket i at dette
spørreskjema kan sendes deg for besvarelse. Idet vi så  langt ikke kan se å ha mottatt et svar tillater
jeg meg å sende skjemaet en gang til og håper at du vil kunne avse 10-15 minutter til å svare på dette.
Hvordan svare på spørreskjemaet? 
Det vil ta ca 10-15 minutter å besvare spørreskjemaet. Besvarelsen kan enten gjøres skriftlig på
skjemaet under eller elektronisk. Velges sistnevnte løsning må det benyttes følgende 
framgangsmåte: 
1. Gå til vår hjemmeside www.ullevål.no/adhd-livet 
2. Velg legeskjema. Du vil da bli viderekoblet til en ekstern, sikker side  
3. Logg deg på med ditt Id-nummer som er: 
4. Svar på spørsmålene og kryss av for ønsket boktittel 
5. Det elektroniske spørreskjemaet har ikke fritekst. Hvis du ønsker å kommentere noe må du derfor 
skrive dette ned og sende til oss. Du må gjerne benytte vedlagte svarkonvolutt til dette.  
Om du skulle ha spørsmål kan undertegnede gjerne kontaktes på telefon 221 175 78 (arbeid), 
414 699 86 (mobil) eller E-post: mien@uus.no   
Som takk for innsatsen kan du velge mellom en av flere nye bøker om ADHD.
På siste side krysser du av for ditt bokønske, og du vil i løpet av kort tid motta ønsket bok pr. post.
Mer og oppdatert informasjon om studien er tilgjengelig på  www.ulleval.no/adhd-livet 
Med vennlig hilsen
Michael B. Lensing
prosjektleder
ADHDlivet
3
4 Daglig dosering er  .........................  mg. (Fortsett med spørsmål 9)
5 Hvorfor ble medikamentell behandling mot ADHD avsluttet? (Kryss av for det som passer)
Bivirkninger Manglende/lite tilfredsstillende effekt Misbruk Bedring
Graviditet Manglende oppmøte Vet ikke
Annet            hva: 
6 Hvilket medikament var det siste pasienten benyttet mot ADHD? (Bare ett kryss)
Ritalin Ritalin kapsler Concerta Dexedrine             Strattera
Annet           hva: 
7 Daglig dosering var ..................... mg.
8 Omtrent hvor lenge fikk pasienten medikamentell behandling mot ADHD? ..............  (tidsperiode) 
(Fortsett med spørsmål 9)
9 Har medikamentell behandlingen mot ADHD ført til:  (Kryss av for hver linje)
Ja          Nei
Psykose
Selvmordstanker
Selvmordsforsøk
10 Har pasienten hatt noen av følgende bivirkninger i mer enn to uker?
(Skal ikke avkrysses om symptomene ikke oppfattes som bivirkninger)
Angst
Blodtrykksøkning
Depresjon
Hjertebank/økt hjerterytme
Hodepine
Irritabilitet
Kvalme
Magesmerter
Nedstemthet
Nervøsitet/uro
Redusert matlyst
Søvnvansker
Tics
Tretthet
Annet, hva
Ikke aktuelt            
11 Har noen av bivirkningene vært så alvorlige at de er meldt til RELIS? Ja                Nei     
APPENDIX III
FEMTI Pluss – en pilotstudie om det å bli godt voksen med ADHD -
spørreskjema
FEMTI PLUSS 
- en pilotstudie om det å bli godt voksen med ADHD
Du er en av ca 300 personer som i følge medlemsregisteret Ɵ l ADHD Norge er 50 år eller eldre og som derfor inviteres 
Ɵ l å delta i denne pilotstudien. Det fi nnes så langt nesten ingen informasjon om det å ha diagnosen ADHD når man 
har passert 50 år. Sammen med ADHD Norge har vi derfor taƩ  iniƟ aƟ v Ɵ l en pilotstudie hvor vi ønsker å få kunnskap 
om akkurat deƩ e. Pilotstudien er i sin helhet fi nansiert av SƟ Ō elsen Helse og Rehabilitering.
Det er frivillig å  delta. Studien er anonymisert. ADHD Norge sender ut spørreskjemaet Ɵ l alle to ganger. Har du svart 
i første runde, kan du se bort fra henvendelsen i runde to. For at resultatene skal bli mest pålitelige, er det vikƟ g at 
fl est mulig svarer.
Vi har skrevet om studien i årets første nummer av STÅ PÅ (lagt ved). Ønsker du mer informasjon, kan du ta kontakt 
med prosjektleder Michael B. Lensing, Regionalt fagmiljø, Oslo universitetssykehus (mien@uus.no). 
På forhånd tusen takk!         Michael B. Lensing     Tor Eikeland (generalsekretær ADHD Norge)
1. Er du kvinne q eller mann q ?
2. Hvor i landet er du bosaƩ ?
 Nord-Norge  q   Midt-Norge  q   Vest-Norge   q 
 Sør-Norge    q Øst-Norge  q
3. I hvilket år er du født? 19 ______
4. Hva er din høyest fullførte utdanning? 
 9-årig grunnskole q  Videregående yrkesfag q 
 Videregående allmenn q  Høyskole/Universitet q 
 Annet q
5. Hva er din sivile status? 
 GiŌ  q  Enke/enkemann q  Skilt/separert q 
 Samboer q  UgiŌ  (aldri vært giŌ ) q
6. Har du noen gang haƩ  inntektsgivende arbeid 
 sammenhengende i minst seks måneder? Ja q Nei q
7. Er du i inntektsgivende arbeid nå? Ja q Nei q
8. Betrakter du deg hovedsakelig som 
 YrkesakƟ v q  Pensjonist q  Trygdet q 
 Hjemmeværende q  Annet q
9. Sammenlignet med for Ɵ  år siden, er din 
 arbeidsevne…
 Mye dårligere q  Noe dårligere q Ingen endring q 
 Noe bedre q  Mye bedre q
10. Sammenlignet med for 10 år siden, er din arbeids 
 lyst… 
 Mye dårligere q Noe dårligere q   Ingen endring q 
 Noe bedre q Mye bedre  q
11. I hvilket år fi kk du diagnosen ADHD? ______________ 
12. Har du fåƩ  medikamentell behandling mot ADHD? 
 Ja q Nei q
13. Bruker du medikamenter mot ADHD nå? Ja q Nei q 
   Hvis ja, hvilket medikament bruker du
 _____________________________________________
 hvilken dose tar du
 _____________________________________________ 
 og hvem skrives resepten ut av, din
 a) psykiater q 
 b) fastlege  q 
 c) eller andre q
SPØRREUNDERSØKELSE - Kryss av for det som passer
DU MÅ GJERNE GI UTFYLLENDE KOMMENTAR
 Send uƞ ylt skjema Ɵ lbake Ɵ l oss i vedlagte
 forhåndsadresserte svarkonvoluƩ 
fortseƩ else neste side...
14. Har du fåƩ  annen type behandling (samtaler, terapi og  
 lignende) mot ADHD? Ja q Nei q
15. Har det å få diagnosen ADHD ført Ɵ l en endring for deg?  
 Ja q Nei q Hvis ja, på hvilken måte? ______________
 _____________________________________________
16. Har du fåƩ  diagnosƟ sert andre sykdommer eller 
 helseskader?  Ja q Nei q Hvis ja, hvilke
 _____________________________________________
17. Tar du andre medikamenter? Ja q Nei q  Hvis ja, hvilke  
 _____________________________________________
18. Hvordan er din hyperakƟ vitet/rastløshet sammenlignet  
 med for Ɵ  år siden? 
 Mye mer q Noe mer q Ingen endring q 
 Noe mindre  q Mye mindre q
19. Hvordan er din impulsivitet sammenlignet med for 
 Ɵ  år siden?
 Mye mer q Noe mer q Ingen endring q 
 Noe mindre q  Mye mindre q
20. Hvordan er din oppmerksomhet sammenlignet med 
 for Ɵ  år siden? 
 Mye dårligere q  Noe dårligere q  Ingen endring q 
 Noe bedre q  Mye bedre q
21. Kryss av for den ruten som best beskriver hvordan du  
har følt og oppført deg de siste seks månedene
a) Hvor oŌ e har du problemer med 
å avsluƩ e en oppgave eƩ er at de 
interessante delene er unnagjort?     q q q q q 
b) Hvor oŌ e er det vanskelig å få 
orden på Ɵ ng når du skal uƞ øre en 
oppgave som krever organisering?     q q q q q 
c) Hvor oŌ e har du problemer med 
å huske avtaler eller forpliktelser?      q q q q q 
d) Når du har en oppgave som krever 
at du tenker nøye igjennom det du 
skal gjøre, hvor oŌ e unngår eller 
utseƩ er du å begynne på den?        q q q q q 
e) Hvor oŌ e siƩ er du og fi kler med 
noe når du siƩ er lenge i ro?        q q q q q 
g) Hvor oŌ e føler du deg overdrevet 
akƟ v og tvunget Ɵ l å gjøre noe, 
som om du var drevet av en 
indre motor?          q q q q q 
   
22. Sammenlignet med for eƩ  år siden, vil du si at din helse  
 nå stort seƩ  er ….?
 Mye verre q  Noe verre q  Omtrent det samme q 
 Noe bedre q  Mye bedre q
23. Bruker du eller har du brukt tobakk/nikoƟ n? 
 Daglig q  Av og Ɵ l q  Sjelden q 
 Aldri q  Før, men ikke nå q
24. Bruker du eller har du brukt alkohol?
 Daglig q  Av og Ɵ l q  Sjelden q 
 Aldri q  Før, men ikke nå q
25. Bruker du eller har du brukt andre rusmidler?
 Daglig q  Av og Ɵ l q  Sjelden q 
 Aldri q  Før, men ikke nå q
26. Hvordan sover du nå sammenlignet med for Ɵ  år siden?
 Mye dårligere q  Noe dårligere q  Ingen endring q 
 Noe bedre q  Mye bedre q
27. Hvordan er din kondisjon/fysiske form nå sammenlignet  
 med for Ɵ  år siden?
 Mye dårligere q  Noe dårligere q  Ingen endring q 
 Noe bedre q  Mye bedre q
28. Mange føler seg yngre eller eldre enn de fakƟ sk er. 
 Hvor gammel føler du deg vanligvis? ___________år
29. Hvor fornøyd er du med din materielle levestandard?
 Svært misfornøyd q  Misfornøyd q  Både og q 
 Fornøyd q Svært fornøyd q
30. Hvor fornøyd er du med din friƟ d?
 Svært misfornøyd q  Misfornøyd q 
 Både og q Fornøyd q  Svært fornøyd q
31. Hvor fornøyd eller misfornøyd er du med diƩ  
 seksualliv nå for Ɵ den?
 Svært misfornøyd q  Misfornøyd q 
 Både og q Fornøyd q  Svært fornøyd q
32. Jeg savner å ha en virkelig nær venn/venninne 
 Svært uenig q  Nokså uenig q 
 Verken enig eller uenig q  Nokså enig q 
 Svært enig q
33. Jeg håndterer dagliglivets krav bra 
 Svært uenig  q Nokså uenig q 
 Verken enig eller uenig q  Nokså enig q  Svært enig q
34. Gjennom livet har mange opplevd store påkjenninger.  
 Har du opplevd noe av det følgende eƩ er at du fylte 
 16 år? Angi din alder omtrent da deƩ e skjedde. 
 Hvis det har skjedd fl ere ganger seƩ  din alder da det 
 sist skjedde.
 
 a)  BruƩ e relasjoner Ɵ l fast parter: 
    Ja  q Nei  q  Alder__________
 b) FåƩ  barn med ADHD: Ja  q Nei  q  Alder__________ 
 c) FåƩ  barnebarn med ADHD: Ja  q Nei  q  Alder______ 
 d) Mistet jobb: Ja  q Nei  q  Alder__________
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 e) Alvorlige økonomiske belastninger/tap:  
   Ja  q Nei  q  Alder__________ 
 f) Livstruende sykdom/skade: 
   Ja  q Nei  q  Alder__________ 
 g) Nære personer alvorlig syke: 
   Ja  q Nei  q  Alder__________
 h) Juridiske problem med reƩ ssak: 
   Ja  q Nei  q  Alder__________ 
 i) UtsaƩ  for vold:  Ja  q Nei  q  Alder__________
 j) UtsaƩ  for seksuelt overgrep: 
   Ja  q Nei  q  Alder__________ 
   
 
35)    Omtrent hvor oŌ e:          
lager du middag nå? q q q q  q q q q q 
gjør du rent nå?         q q q q  q q q q q 
gjør du innkjøp nå?   q q q q  q q q q q 
får du besøk nå?        q q q q  q q q q q 
går du på besøk nå?  q q q q  q q q q q 
hjelper du andre 
utenom nær 
familie nå?                  q q q q  q q q q q
bruker du Ɵ d på 
dine hobbyer nå?      q q q q  q q q q q
blir du irritert nå?      q q q q  q q q q q
36.  Omtrent hvor oŌ e tar du deg av barnebarn?
  Aldri q  Sjeldnere q   Noen ganger i året q 
  Hver måned, men ikke hver uke    q 
  Hver uke, men ikke daglig    q   Daglig    q 
  Har ingen barnebarn    q
37.  Nedenfor kommer en rekke påstander om hvordan du 
   har det nå, og hvordan du forholder deg Ɵ l ulike sider 
   ved livet. Hvor enig eller uenig er du når du tenker på 
   deg selv for Ɵ den? 
a)   På de fl este måter er livet miƩ  nær det ideelle
   Svært uenig q   Nokså uenig q  
   Verken enig eller uenig q   Nokså enig q   Svært enig q
b) Mine livsforhold er utmerkede
 Svært uenig q   Nokså uenig q 
 Verken enig eller uenig q   Nokså enig q   Svært enig q
c) Så langt har jeg fåƩ  det vikƟ gste jeg ønsket meg i livet
 Svært uenig q   Nokså uenig q 
 Verken enig eller uenig q   Nokså enig q 
 Svært enig q
d) Jeg er Ɵ lfreds med livet miƩ 
 Svært uenig q   Nokså uenig q 
 Verken enig eller uenig q   Nokså enig q 
 Svært enig q
e) Hvis jeg kunne leve livet miƩ  om igjen, ville jeg ikke 
 forandre på nesten noen Ɵ ng
 Svært uenig q   Nokså uenig q   
 Verken enig eller uenig q   Nokså enig q 
 Svært enig q
38. Kommentarer: 
_______________________________________________
_______________________________________________
_______________________________________________
_______________________________________________
_______________________________________________
_______________________________________________
_______________________________________________
_______________________________________________
 
_______________________________________________
_______________________________________________
39. Vis hvilke utsagn som passer best på din helseƟ lstand i dag ved å seƩ e et kryss i en av 
 rutene utenfor hver av gruppene nedenfor.
Gange
Jeg har ingen problemer med å gå omkring. q
Jeg har liƩ  problemer med å gå omkring. q 
Jeg er sengeliggende. q
Personlig stell
Jeg har ingen problemer med personlig stell. q
Jeg har liƩ  problemer med å vaske meg eller kle meg. q
Jeg er ute av stand Ɵ l å vaske meg eller kle meg. q
Vanlige gjøremål (f.eks. arbeid, studier, husarbeid,
familie- eller friƟ dsakƟ viteter). 
Jeg har ingen problemer med å uƞ øre mine vanlige gjøremål. q
Jeg har liƩ  problemer med å uƞ øre mine vanlige gjøremål. q
Jeg er ute av stand Ɵ l å uƞ øre mine vanlige gjøremål. q
Smerte/ubehag
Jeg har verken smerte eller ubehag. q
Jeg har moderat smerte eller ubehag. q
Jeg har sterk smerte eller ubehag. q
40. Din helseƟ lstand, se informasjon og skala
Angst/depresjon
Jeg er verken engstelig eller deprimert. q
Jeg er noe engstelig eller deprimert. q
Jeg er svært engstelig eller deprimert. q
HELSETILSTANDEN
For å hjelpe folk Ɵ l å si hvor god eller dårlig en helseƟ lstand er, 
har vi laget en skala (omtrent som et termometer) 
hvor den beste Ɵ lstanden du kan tenke deg er merket 100 og den 
verste Ɵ lstanden du kan tenke deg er merket 0.
Vi vil gjerne at du viser på denne skalaen hvor god eller dårlig 
helseƟ lstanden din er i dag, eƩ er din oppfatning. 
Vær vennlig å gjøre deƩ e ved å trekke en linje fra den sorte boksen 
“Din helse i dag” Ɵ l det punktet på skalaen som viser hvor god 
eller dårlig din helseƟ lstand er i dag.
Verst tenkelige helseƟ lstand
Best tenkelige
helseƟ lstand
DIN HELSESTILSTAND
IDAG
Din 
helse 
i dag
TAKK FOR HJELPEN! 
Husk å poste besvarelsen
Notes
Notes
